Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.
Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.
A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.
A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.
Substances that reduce the growth or reproduction of BACTERIA.
Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins.
A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection.
Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
A species of gram-negative, aerobic bacteria, commonly found in the clinical laboratory, and frequently resistant to common antibiotics.
Infections with bacteria of the genus ACINETOBACTER.
The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
A genus of gram-negative bacteria of the family MORAXELLACEAE, found in soil and water and of uncertain pathogenicity.
A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.
A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.
EXOPEPTIDASES that specifically act on dipeptides. EC 3.4.13.
Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method.
Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.
Gram-negative bacteria occurring in the lower intestinal tracts of man and other animals. It is the most common species of anaerobic bacteria isolated from human soft tissue infections.
Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams.
The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.
Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans.
Infections with bacteria of the genus PSEUDOMONAS.
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.
Infections with bacteria of the family ENTEROBACTERIACEAE.
A family of gram-negative, facultatively anaerobic, rod-shaped bacteria that do not form endospores. Its organisms are distributed worldwide with some being saprophytes and others being plant and animal parasites. Many species are of considerable economic importance due to their pathogenic effects on agriculture and livestock.
A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed)
Bacterial proteins that share the property of binding irreversibly to PENICILLINS and other ANTIBACTERIAL AGENTS derived from LACTAMS. The penicillin-binding proteins are primarily enzymes involved in CELL WALL biosynthesis including MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE; PEPTIDE SYNTHASES; TRANSPEPTIDASES; and HEXOSYLTRANSFERASES.
A broad-spectrum antimicrobial carboxyfluoroquinoline.
A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
Infections with bacteria of the genus KLEBSIELLA.
Porins are protein molecules that were originally found in the outer membrane of GRAM-NEGATIVE BACTERIA and that form multi-meric channels for the passive DIFFUSION of WATER; IONS; or other small molecules. Porins are present in bacterial CELL WALLS, as well as in plant, fungal, mammalian and other vertebrate CELL MEMBRANES and MITOCHONDRIAL MEMBRANES.
Any infection which a patient contracts in a health-care institution.
Bacteria which retain the crystal violet stain when treated by Gram's method.
Enzyme which catalyzes the peptide cross-linking of nascent CELL WALL; PEPTIDOGLYCAN.
Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in water, sewage, soil, meat, hospital environments, and on the skin and in the intestinal tract of man and animals as a commensal.
A semi-synthetic antibiotic related to penicillin.
Therapy with two or more separate preparations given for a combined effect.
Enzymes that catalyze the transfer of hexose groups. EC 2.4.1.-.
Inflammation of the lung parenchyma that is caused by bacterial infections.
Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.
Acyltransferases that use AMINO ACYL TRNA as the amino acid donor in formation of a peptide bond. There are ribosomal and non-ribosomal peptidyltransferases.
Proteins found in any species of bacterium.
Infections with bacteria of the genus BACTEROIDES.
Semisynthetic broad-spectrum cephalosporin.
A semisynthetic cephamycin antibiotic resistant to beta-lactamase.
Infections by bacteria, general or unspecified.
Gram-negative gas-producing rods found in feces of humans and other animals, sewage, soil, water, and dairy products.
A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.
Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
Electrophoresis in which a pH gradient is established in a gel medium and proteins migrate until they reach the site (or focus) at which the pH is equal to their isoelectric point.
A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065)

In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems. (1/848)

CL 188,624, CL 190,294, and CL 191,121 are novel aminomethyl tetrahydrofuranyl (THF)-1 beta-methylcarbapenems. The in vitro antibacterial activities of these THF carbapenems were evaluated and compared with those of biapenem, imipenem, and meropenem against 554 recent clinical isolates obtained from geographically distinct medical centers across North America. The antibacterial activities of the THF carbapenems were equivalent to that of biapenem, and the THF carbapenems were slightly more active than imipenem and less active than meropenem against most of the members of the family Enterobacteriaceae but lacked significant activity against Pseudomonas isolates. In general, CL 191,121 was two- to fourfold more active than CL 188,624 and CL 190,294 against the staphylococcal and enterococcal isolates tested. CL 191,121 was twofold less active than imipenem against methicillin-susceptible staphylococci and was as activity as imipenem against Enterococcus faecalis isolates. Biapenem and meropenem were two- and fourfold less active than CL 191,121, respectively, against the methicillin-susceptible staphylococci and E. faecalis. All the carbapenems displayed equivalent good activities against the streptococci. Biapenem was slightly more active than the other carbapenems against Bacteroides fragilis isolates. Time-kill curve studies demonstrated that the THF carbapenems were bactericidal in 6 h against Escherichia coli and Staphylococcus aureus isolates. The postantibiotic effect exerted by CL 191,121 was comparable to or slightly longer than that of imipenem against isolates of S. aureus, E. coli, and Klebsiella pneumoniae.  (+info)

Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin. (2/848)

Viable cells of Pseudomonas aeruginosa were entrapped in alginate gel layers and incubated in a minimal glucose (15 g/L)-yeast extract (2 g/L)-salt medium to form artificial biofilm-like structures. After cultivation for 2 days, the biomass distribution inside the polymer was highly heterogeneous. The cell number reached approximately 1011 cells/g gel in the outer regions of the gel structures whereas the inner areas were less colonized (c. 10(8) cells g/gel). Killing of immobilized organisms by imipenem and tobramycin were compared with free-cell experiments (inoculum c. 10(9) cells/mL). Sessile-like bacteria displayed a higher resistance to the two antibiotics used alone or in combination than did suspended cells. Exposure for 10 h to 20 x MIC imipenem and 15 x MIC tobramycin reduced the number of viable immobilized bacteria to 0.3% and 3%, respectively, of the initial cell population, whereas these antibiotic concentrations were much more efficient (bactericidal) against free-cell cultures (5 log kill in 6 h). A synergic effect of tobramycin and imipenem was detected on bacterial suspensions but not on biofilm-like structures. Effective diffusivity measurements showed that the diffusion of imipenem in the alginate layer was not hindered. A slight but significant enhancement of beta-lactamase induction in immobilized cells as compared with their suspended counterparts was insufficient to explain the high resistance of sessile-like bacteria.  (+info)

In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem. (3/848)

We have evaluated the ability of imipenem and meropenem to select, in vitro, resistant mutants of two clinical isolates of Klebsiella pneumoniae producing both SHV and TEM beta-lactamases. Only meropenem selected mutants of both isolates for which the MICs of meropenem, but not imipenem, were markedly higher than those for the parent strains; the MICs of several other beta-lactam antibiotics, including beta-lactam/beta-lactamase inhibitor combinations, for these mutants were also higher than those for the parent strains. In contrast, the MICs for the imipenem-selected mutants were the same as, or similar to, those for the parent strains. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis analysis revealed that an outer membrane protein in both parent strains was absent in the meropenem-selected mutants, but not in the imipenem-selected mutants. This protein is likely to be a porin, the absence of which is presumably associated with impaired beta-lactam permeability and, therefore, the reduced susceptibilities to these antibiotics exhibited by the mutant strains. We believe that this is the first report of the in-vitro selection of porin-deficient mutants of K. pneumoniae following exposure to meropenem.  (+info)

Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. (4/848)

Pseudomonas aeruginosa OprD is a specific porin which facilitates the uptake of basic amino acids and imipenem, a carbapenem antibiotic. Resistance to imipenem due to the loss of OprD is an important mechanism for the loss of clinical effectiveness. To investigate the negative regulatory mechanisms influencing oprD expression, a gene upstream of the coregulated mexEF-oprN efflux operon, designated mexT, was cloned. The predicted 304-amino-acid mature MexT protein showed strong homology to LysR-type regulators. When overexpressed it induced the expression of the mexEF-oprN efflux operon while decreasing the level of expression of OprD. The use of an oprD::xylE transcriptional fusion indicated that it acted by repressing the transcription of oprD. Salicylate, a weak aromatic acid known to reduce porin expression and induce low levels of multiple antibiotic resistance in Escherichia coli, was able to induce imipenem resistance and reduce the expression of OprD but not multiple antibiotic resistance or OprN expression in P. aeruginosa. This was also demonstrated to occur at the level of transcription. Acetyl salicylate and benzoate, but not catechol, were also able to reduce the levels of OprD in the P. aeruginosa outer membranes. These OprD-suppressing compounds increased imipenem resistance even in a mexT-overexpressing and nfxC mutant backgrounds, suggesting that such resistance is independent of the MexT repressor and that oprD is influenced by more than a single mechanism of repression.  (+info)

In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group. (5/848)

A total of 3903 pathogens from 48 Canadian medical centres were tested against 19 antimicrobial agents. Five agents showed activity against > or = 90% of all 1982 respiratory tract pathogens tested (ciprofloxacin, 90%; cefoperazone, 91%; ticarcillin/clavulanate, 92%; ceftazidime and imipenem, 93% each). Nine agents had > or = 90% activity against Enterobacteriaceae from respiratory tract infection (cefotaxime and ticarcillin/clavulanate, 90% each; aztreonam, ceftizoxime and ceftriaxone, 91% each; ceftazidime, 93%; ciprofloxacin, 97%; imipenem and netilmicin, 98% each). Similarly, five agents had activity against > or = 90% of all 1921 urinary tract pathogens tested (ciprofloxacin and ticarcillin/clavulanate, 90% each; cefoperazone and netilmicin, 91% each; imipenem, 99%). Nine agents had > or = 95% activity against Enterobacteriaceae from urinary tract infection (ciprofloxacin, 95%; cefotetan, 97%; aztreonam, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone and netilmicin, 98% each; imipenem, 99%). Seventeen agents had activity against > or = 95% of Staphylococcus aureus strains. Susceptibility of Pseudomonas aeruginosa isolates ranged from 2% to 91%.  (+info)

Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. (6/848)

Several lower respiratory tract infection (LRTI) trials have documented a correlation between clinical response and area under the inhibitory curve (24 h AUC/MIC; AUIC). The AUIC values in these studies were based on measured MICs and measured serum concentrations. This study evaluates AUIC estimates made using population pharmacokinetic parameters, and MICs from an automated microbiological susceptibility testing system. A computer database review over 2 years yielded 81 patients at Millard Fillmore Hospital with a culture-documented gram-negative LRTI who had been treated with piperacillin and an aminoglycoside, ceftazidime, ciprofloxacin or imipenem. Their AUIC values were estimated using renal function, drug dosages and MIC values. Outcome groups (clinical and microbiological cures and failures) were related to the AUIC values using Kruskal-Wallis ANOVA, linear regression and classification and regression tree (CART) analysis. A significant breakpoint for clinical cures was an AUIC value at least 72 SIT(-1) x 24 h (inverse serum inhibitory titre integrated over time). All antibiotics performed significantly better above this value than below it. Clinical cure was well described by a Hill-type equation. Within the piperacillin/aminoglycoside regimen, most of the activity came from the piperacillin, which had a higher overall AUIC value than the aminoglycoside. AUIC estimations based upon MIC values derived from the automated susceptibility testing method differed from NCCLS breakpoint data and from tube dilution derived values in this hospital by as much as three tube dilutions. These automated methods probably overestimated the MIC values of extremely susceptible organisms. The lack of precise MIC estimates in automated clinical microbiology methods impairs the use of AUIC to prospectively optimize microbiological outcome. Even ignoring this limitation and using the values as they are reported, the results of this analysis suggest that AUIC targets between 72 and 275 SIT(-1) x 24 h are useful in predicting clinical outcome.  (+info)

Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. (7/848)

A recent multicentre clinical study evaluated the safety and efficacy of i.v. ciprofloxacin therapy compared with imipenem-cilastatin in hospitalized patients with severe pneumonia. Monotherapy with i.v. ciprofloxacin was at least equivalent to imipenem in terms of bacteriological eradication and clinical response. In a single-centre, retrospective, post-therapy evaluation of persistent and subsequent infection, the incidence of gram-negative infections and associated costs were compared. The main elements of the economic analysis included costs of additional antimicrobial therapy and hospitalization. Thirty-two patients were randomized into the study, of whom 27 were efficacy-valid. The 13 patients randomized into the ciprofloxacin group were not significantly different from the 14 patients in the imipenem group in terms of clinical parameters. Clinical cure occurred in ten of 13 patients (77%) in the ciprofloxacin group and in seven of 14 (50%) in the imipenem group. Bacteriological eradication was achieved in 11 of 13 (85%) ciprofloxacin-treated and eight of 14 (57%) imipenem-treated patients. Five of 13 (38%) patients in the ciprofloxacin group and nine of 14 (64%) in the imipenem group experienced persistent or subsequent infection requiring post-treatment antimicrobials. In these five ciprofloxacin patients, three had cultures with gram-positive organisms only and two had cultures with both gram-positive and gram-negative organisms. In the nine imipenem-treated patients requiring post-study antimicrobials, all had gram-negative bacteria and three also had gram-positive organisms. The incidence of subsequent gram-negative infection in the two groups (15% vs 64%) was significantly different (P < 0.05). Pseudomonas aeruginosa was isolated from seven patients in the imipenem group but only one in the ciprofloxacin group (P < 0.05). Subsequent costs for post-therapy antimicrobials and hospital stay while receiving study and post-study drug therapy were evaluated; the cost per patient cure was US$29,000 for ciprofloxacin and US$76,000 for imipenem. Initial treatment of severe pneumonia with ciprofloxacin resulted in significantly less subsequent gram-negative infection and was associated with substantially lower curative costs.  (+info)

Multiple roles for IL-12 in a model of acute septic peritonitis. (8/848)

The present study addressed the role of IL-12 in a murine model of septic peritonitis, induced by cecal ligation and puncture (CLP). Although CLP surgery induced IL-12 production at 6 and 24 h after surgery, IL-12 immunoneutralization was clearly deleterious in this model: 54% of CLP mice receiving preimmune serum survived, whereas mice administered IL-12 antisera prior to CLP experienced a 25% survival rate. IL-12 immunoneutralization not only led to increased mortality, but also appeared to promote a shift away from IL-12 and IFN-gamma, in favor of IL-10. This cytokine shift corresponded to changes in bacterial load, as CLP mice receiving IL-12 antiserum yielded more CFUs from the peritoneal cavity at 24 h after CLP. To address the role of bacterial infection in IL-12 antiserum-induced mortality following CLP, antibiotics were administered for 4 days after surgery. Despite regular antibiotic administration, IL-12 immunoneutralization still reduced survival in CLP mice. Furthermore, histology of the ceca revealed that mice administered IL-12 antisera failed to show typical organization of the damaged cecum wall. Accordingly, Gram staining revealed bacteria within peritoneal fluids from these mice, while peritoneal fluids from CLP mice that received preimmune serum and antibiotics were free of bacteria. Altogether, these data suggested multiple important roles for IL-12 in the evolution of murine septic peritonitis.  (+info)

Volume 48, no. 1, p. 224-228, 2004. Page 224, column 2, line 16: risk of IRAB infection should read risk of IRAB occurrence.. Page 225, column 2, line 49: IRAB should read imipenem-resistant Pseudomonas aeruginosa.. Page 225, column 2, line 51: ISAB should read imipenem-susceptible P. aeruginosa.. ...
TY - JOUR. T1 - Topical imipenem therapy of aminoglycoside-resistant pseudomonas keratitis in rabbits. AU - Sawusch, M. R.. AU - OBrien, Terrence. AU - Valentine, J.. AU - Dick, J. D.. AU - Gottsch, J. D.. PY - 1988/1/1. Y1 - 1988/1/1. N2 - We used a rabbit model of bacterial keratitis to assess in vivo efficacy of topical imipenem, a highly potent β-lactam antibiotic with an unusually broad spectrum of activity, including aminoglycoside-resistant Pseudomonas aeruginosa. Albino rabbits received intrastromal injections of 5 x 102 organisms of an aminoglycoside-resistant strain of P. aeruginosa. At five hours postinoculation, imipenem (5 mg/ml) therapy was initiated using one drop per 30 minutes for 12 hours. Corneal tissue was then excised for colony forming unit counts. Imipenem was highly effective in reducing colony forming unit counts to zero in comparison to 4.1 x 105 organisms for untreated controls. A second regimen beginning 24 hours postinoculation of one drop per hour for 24 hours was ...
Imipenem is a carbapenem antibacterial agent with a broad spectrum of activity against Gram-negative and Gram-positive bacteria. This agent is often used as the last line of therapy for highly resistant Gram negative bacilli nosocomial infections. In common with other beta-lactamase inhibitor, the main pharmacokinetic/pharmacodynamic (PK/PD) index that correlates with the therapeutic efficacy is the time that concentrations in the tissue and serum are above the MIC and administration by continuous infusion is the preferred mode of administration to maximize this parameter.. However, in tropical countries, the stability of carbapenem antibiotics is an important consideration when considering continuous infusion. Therefore, prolonged infusion may be a useful mode of administration to maximize bactericidal activity. This study will demonstrate the stability of imipenem in clinical use at room temperature in tropical countries. ...
The use of imipenem antibiotics to treat A. baumannii infections as the premier agents continued well in the 1990s. Despite the growing incidence of resistance, the level of imipenem use remained relatively high. The persistence of its use in clinical settings can be explained by its superior activity against A.baumannii compared to other antimicrobial agents, even with its growing resistance[63]. As the resistance of imipenem continued to grow, another bacteriostatic carbapenem began to be used in greater frequency-meropenem. In addition to be a broad-spectrum agent against gram-negative bacteria, meropenem is also less likely to cause seizures than imipenem[64]. Besides the continued the use of carbapenems, the combination of anti-A.baumannii agents was a major therapeutic strategy employed in the 1990s. The main purpose of these pairings was to put together drugs that would have similar effects as a monotherapy drug of the same class. This usually involved pairing a drug with high resistance ...
Imipenem/relebactam answers are found in the Johns Hopkins ABX Guide powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
PCR amplification and complete sequencing of the ARI-1 gene.PCRs were carried out in 100-μl volumes containing 16 mM (NH4)2SO4, 67 mM Tris-HCl (pH 8.8), 0.1% Tween 20 buffer, 2.5 mM MgCl2, 0.2 mM deoxynucleoside triphosphates (Amersham Pharmacia Biotech UK Ltd.), 0.1 to 0.5 μM each primer, and 1 U of BIOTAQ polymerase (Bioline UK Ltd., London, United Kingdom) or 1.25 U of Pfu DNA polymerase (Promega UK Ltd., Southampton, United Kingdom). Template DNA was boiled for 10 min before being added to the reaction mixture. DNA amplification was performed in an Omn-E thermal cycler (Hybaid Ltd., Teddington, United Kingdom) under the following cycle conditions: 94°C for 5 min, 60°C for 1 min, 72°C for 2 min (one cycle); 94°C for 15 s, 60°C for 1 min, 72°C for 2 min (30 cycles); and a final extension of 72°C for 5 min (one cycle). PCR products containing the 3′ end of the ARI-1 gene were obtained by inverse PCR of HincII orSau3A fragments of pUK1356 by using the primer pairs P1-P2 and ...
Objective: To evaluate the in vitro activity of the fourth-generation cephalosporin cefpirome in comparison to that of ceftazidime, ceftriaxone, cefotaxime and imipenem in a multicenter study involving nine hospitals from six cities (four states). Material and methods: A total of 804 isolates from patients hospitalized in either intensive care units or Oncology/Hematology units was evaluated. The isolates were collected between June and November of 1995, i.e. before cefpirome became commercially available in Brazil, and susceptibility tested by broth microdilution following the NCCLS procedures. All isolates resistant to cefpirome were retested by B-test. Results: Against Enterobacteriaceae (n = 344), cefpirome demonstrated an activity 2 to 32-fold higher than that of the third-generation cephalosporins (TGCs) and similar to that of imipenem. The percentages of Enterobacteriaceae susceptible were: 88%, 69% and 96% for cefpirome, TGCs and imipenem, respectively, The cefpirome spectrum were ...
Results: In this study, among 700 patients with nosocomial pneumonia, 364 and 336 of those were male and female, respectively. All of these received imipenem. Of the total patients, 317 cases (45%) were resistant to imipenem. 84% of these patients were cured and the remaining 16% expired (P value = 0.001). A. baumannii resistance to the imipenem in both hospitals had an increasing rate. The resistance rate in the Ghaem hospital increased 96.6% at the end of the period compared to beginning of study (P value = 0.004). Also, a similar increase (94.7%) was observed in the Imam Reza hospital (P value = 0.003). ...
Savior Lifetec is a leading specialty injectable pharmaceutical company with headquarters in Chunan, Taiwan. Our state of the art facilities are vertically integrated, capable of producing sterile API and finished dosage formulations. Our facilities comply with the highest quality standards, having passed inspections by authorities from the US, EU, and Japan.
we identified 1,805 gram-negative organisms in cultures of urine samples obtained over a 10-month period from residents of 63 long-term care facilities. the prevalence of fluoroquinolone resistance in escherichia coli was 51% (446 of 874 isolates), whereas the prevalences of ceftazidime and imipenem resistance in klebsiella species were 26% and 6% (84 and 19 of 323 isolates), respectively. the prevalence of resistance varied significantly by facility type, size, and geographic location ...
Lemibet I.M. is mainly associated with symptoms and indications-The International Classification of Diseases (ICD)- J01DH51-Imipenem and enz.... ...
Best Imipenem Cilastatin Injection Dealers. Find the list of best Imipenem Cilastatin Injection suppliers & Manufacturers. Yellow Pages Directory of Imipenem Cilastatin Injection, Imipenem Cilastatin Injection manufacturers, Traders, and Imipenem Cilastatin Injection, Imipenem Cilastatin Injection Suppliers & Dealers in India.
Imipenem/cilastatin has the ability to kill a wide variety of bacteria. Imipenem is the active antibiotic agent and works by interfering with their ability to form cell walls, so the bacteria break up and die. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase if administered alone (making it less effective); the metabolites can cause kidney damage.[11] Imipenem is a broad-spectrum betalactam antibiotic used for severe bacterial infections caused by susceptible organisms. Because imipenem is rapidly inactivated by renal dehydropeptidase I, it is given in combination with cilastatin, a DHP-I inhibitor which increases half-life and tissue penetration of imipenem. Imipenem/cilastatin, like other carbapenems, binds to bacterial penicillin-binding proteins and interferes with bacterial cell wall integrity and synthesis. It has activity against many aerobic and anaerobic Gram-positive and Gram-negative organisms, including Staphylococcus aureus, Streptococcus pyogenes, S. agalactiae, S. ...
Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital Wissam K Kabbara, George T Nawas, Wijdan H RamadanDepartment of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon Background: Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin. Methods: This observational study was conducted in a tertiary care hospital over a 3-month period. The treatment of 100 patients with imipenem
Despite advances in prevention and treatment, hospital-acquired pneumonia remains a significant problem as the second most common infection acquired in the hospital and the most deadly (20%-50% of patients who acquire pneumonia while in the hospital die from complications of pneumonia). Levofloxacin has been shown in clinical trials to be effective against a number of different bacteria, including those found to be common and uncommon causes of pneumonia. This multicenter, open-label study evaluates the safety and effectiveness of levofloxacin as compared with imipenem/cilastatin, another type of antibiotic treatment, in patients with pneumonia acquired in the hospital. Patients receive treatment for a total of 7-15 days, initially with levofloxacin or imipenem/cilastatin, administered slowly through a vein. If patients respond positively to either drug, treatment may be changed to levofloxacin or ciprofloxacin (if initially treated with imipenem/cilastatin), to be taken by mouth. Certain ...
Introduction: Surgical wound infection is a serious problem, especially with metallo-beta lactamases (MBLs)- producing gram-negative bacteria as Pseudomonas aeruginosa. The main objective of this work was to evaluate for the first time in Minia- Upper Egypt, the incidence of imipenem-resistant Pseudomonas aeruginosa infection of surgical wounds particularly that mediated by MBL production.. Methodology: P. aeruginosa was isolated from infected wounds by swabs and underwent full microbiological identification and Antibiotic Susceptibility testing. MBL production was tested by E-test and PCR was used for imipenemase (blaIMP) and Verona integron-encoded metallo-beta-lactamase (blaVIM) gene detection.. Results: Out of 200 pus samples collected from surgical site infections, P. aeruginosa had the prevalence rate of 35%. Imipenem resistance was found in 28.57% of the isolated Pseudomonas aeruginosa. The prevalence of MBL-producing isolates among Imipenem-resistant P. aeruginosa (IRPA) was 85 % by ...
QUEPREON BIOLOGICALS PVT LTD. - Manufacturer & Supplier of Imipenem Cilastatin For Injection Usp 250 Mg based in Bengaluru, India
Cilastatin; Imipenem information about active ingredients, pharmaceutical forms and doses by Jodas Expoim, Cilastatin; Imipenem indications, usages and related health products lists
Cilastatin; Imipenem information about active ingredients, pharmaceutical forms and doses by Ranbaxy, Cilastatin; Imipenem indications, usages and related health products lists
Imipenem is an antibiotic that fights bacteria. Cilastatin helps imipenem work more effectively by preventing the breakdown of the antibiotic in the kidneys. Imipenem and cilastatin is a combination medicine used to treat severe infections of the lower respiratory tract, skin, stomach, or female reproductive organs...
Imipenem, the first clinically used carbapenem, was developed at Merck and Co. It was approved for use in the United States in 1985.[20] Imipenem is hydrolyzed in the mammalian kidney by a dehydropeptidase enzyme to a nephrotoxic intermediate, and thus is co-formulated with the dehydropeptidase inhibitor cilastatin.[5] Imipenem is available in both intravenous[21] and intramuscular[22] formulations.. Meropenem is stable to mammalian dehydropeptidases and does not require co-administration of cilastatin. It was approved for use in the United States in 1996. In most indications it is somewhat more convenient to administer than imipenem, 3 times a day rather than 4. Doses of less than one gram may be administered as an IV bolus, whereas imipenem is usually administered as a 20-minute to one hour infusion. Meropenem is somewhat less potent than imipenem against gram-positive pathogens, and somewhat more potent against gram-negative infections. Unlike imipenem, which produced an unacceptable rate of ...
Medscape - Indication-specific dosing for Primaxin (imipenem/cilastatin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.
Buy Zienam 500 mg Injection, Imipenem 500 mg Injection and Cilastatin 500 mg in India, China, Russia and UAE at Lowest Price? Contact us for more detail about Imipenem 500 mg & Cilastatin 500 mg. Manufactured by MSD Pharmaceuticals Pvt Ltd in India Visit our website or call us at: 1-800-496-1779, Visit @Thecureinternational.com
BioAssay record AID 56107 submitted by ChEMBL: Stability towards hog kidney dehydropeptidase (DHP) expressed as relative hydrolysis to imipenem.
PRIMAXIN IM 500 (Cilastatin sodium,Imipenem) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
PRIMAXIN IM 500 (Cilastatin sodium,Imipenem) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
PRIMAXIN IM 500 (Cilastatin sodium,Imipenem) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
Review the selected safety information for RECARBRIO™ (imipenem, cilastatin, and relebactam), and read the prescribing information for RECARBRIO before prescribing.
While studies have clearly shown a link between antibiotics and the release of endotoxins and the effect of endotoxins and cytokines in precipitating an inflammatory response as well as septic shock, it has remained to be seen if this correlates with clinical outcome. There have been few prospective human studies into the administration of different antibiotics in the treatment of gram negative sepsis. One pertinent randomized study by Prins and colleagues of urosepsis patients treated with imipenem compared to ceftazidime found a more rapid defervescence with the administration of imipenem. Endotoxin and cytokine release also increased after administration of ceftazidime compared to no increase in the imipenem group. However in other physiological measures and mortality, there were no differences between the two study groups. Another study by Byl and colleagues examined again the difference between imipenem and ceftazidime in human septic patients. While both antibiotics did appear to induce ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Buy Best Prescription Drugs Available Online with FDA Approved Prescription Medications. Our goal is to provide you with the best value on prescription drugs & use our personal prescription system which ultimately leads you to live longer and healthier life.
This article explores both national and regional trends in rates of Acinetobacter resistance to imipenem, an antibiotic often reserved as a last-line treatment for infections.
To know the drug resistance of (AB) in wound of children with traffic injury and its relationship with antibiotic use. Wound exudate of 226 children with traffic injury admitted to our unit from January 2010 to December 2015 were collected. API bacteria identification panels and fully automatic microbiological identification system were used to identify pathogens. Kirby-Bauer paper disk diffusion method was used to detect the drug resistance of pathogens to 18 antibiotics including amoxycillin/clavulanic acid, piperacillin/tazobactam, and imipenem. The detection situation of pathogen of childrens wounds and drug resistance of detected AB to 18 antibiotics in each year were collected. Forty-six AB positive children (2 children excluded) were divided into imipenem-resistant group (IR, =19) and non imipenem-resistant group (NIR, =25) according to whether AB was 100% resistant to imipenem. Drug resistance of AB in wounds of children to 18 antibiotics in two groups was compared. The antibiotic use ...
Differentiating reinfection from the acquisition of resistance in strains of Pseudomonas aeruginosa after antimicrobial therapy is difficult because currently used epidemiological markers are not stable genetic markers. We previously established that a 741-base pair PstI-NruI restriction fragment up …
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
COMPARISON BETWEEN MONOTHERAPY WITH IMIPENEM/CILASTATIN SODIUM (IPM/CS) AND COMBINATIONS OF IPM/CS AND OTHER DRUGS FOR TREATING BACTERIAL INFECTIONS IN PATIENTS WITH HEMATOPOIETIC DISORDERS (1996 ...
Results: 251(33.2%) bacteria were isolated out of a total of 757 specimen submitted for analysis within the period under review. 17(6.8%) were E.coli; 16 were from soft tissue specimen and one from blood. There was no isolate of E.coli from CSF. Most of the isolates were resistant to commonly used antibiotics for treatment of neonatal infections. Three isolates were resistance to amoxicillin-clavulanate and ceftriaxone. One isolate was resistance to amoxicillin-clavulanate, ceftriaxone and imipenem. 100% and 80% of the strains tested were susceptible to amikacin and imipenem respectively ...
Ilyin, L. A., V. Yu. Soloviev, A. E. Baranov, A. K. Guskova, N. M. Nadezhina, and I. A. Gusev, May 2004, Early medical consequences of radiation incidents in the former URRS territory, 11th International Congress of IRPA, on line, IRPA [http://irpa11.irpa.net/pdfs/7c20.pdf]. ...
Akinesia / CC BY-SA Gram positive and Gram negative Amoxicillin-clavulanateTazobactam-piperacillinCarbapenem: Ertapenen, Imipenem…
Drugs with less than 10 isolates are removed from the chart and from the graph. The following drugs had some data removed: gentamicin, quinupristin/dalfopristin, imipenem. ...
TY - JOUR. T1 - Integron-associated imipenem resistance in Acinetobacter baumannii isolated from a regional hospital in Taiwan. AU - Liu, S. Y.. AU - Lin, J. Y.. AU - Chu, C.. AU - Su, L. H.. AU - Lin, T. Y.. AU - Chiu, C. H.. PY - 2006/1. Y1 - 2006/1. N2 - We investigated the genetic properties of imipenem-resistant Acinetobacter baumannii collected from a regional hospital in Taiwan. Pulsed-field gel electrophoresis demonstrated that the isolates were genetically diverse. Polymerase chain reaction, DNA sequencing, and DNA-DNA hybridisation showed that the blaIMP-1 gene resided as a cassette in a plasmid-borne class 1 integron in two isolates. The majority of the resistant isolates were plasmid-less and carried no blaIMP, blaVIM or bla CFI genes, indicating that other uncharacterised metallo-β- lactamases or mechanisms other than enzyme production are involved in carbapenem resistance in this group of A. baumannii. We conclude that multidrug resistance of A. baumannii was a combined effect of ...
Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Dehydropeptidase is an enzyme found in the kidney and is responsible for degrading the antibiotic imipenem. Cilastatin can therefore be combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its antibacterial effect. Imipenem alone is an effective antibiotic and can be given without the cilastatin. Cilastatin itself does not have antibiotic activity although it has been proved to be active against a zinc-dependent beta-lactamase that usually confer antibiotic resistance to certain bacteria; more precisely the carbapenem family of antibiotics. This property is due to the physico-chemical similarities between membrane dipeptidase (MDP), the compound it is usually set to target, and the bacterial metallo-beta-lactamase carried by the CphA gene Therefore, cilastatin is considered a beta-lactamase inhibitor, not an antibiotic per se. But as with other combinations of an ...
The problem of multi-drug resistance in clinical isolates of A. baumannii has led to widespread use of polymyxins for the treatment of severe infections with this organism. Several studies have evaluated the ability of other agents to produce synergy when combined with polymyxin in-vitro [4, 5]. The aims of the present study were therefore two-fold; firstly to determine the in-vitro efficacy of polymyxin in combination with other agents against epidemic UK A. baumannii clones, and secondly, to evaluate the use of rapid methods of testing antibiotic synergy which could be employed in routine clinical practice.. We were unable to show synergy with either imipenem, rifampicin or azithromycin in combination with polymyxin for any of the OXA-23 clone 1 isolates. For the OXA-23 clone 2 isolate synergy was observed (FICI = 0.5) with polymyxin in combination with rifampicin or imipenem The clinical relevance of this synergy can be debated as the MIC to imipenem in combination with polymyxin was still 8 ...
The success rate of the clinical response to treatment of severe nosocomial pneumonia in patients requiring mechanical ventilation was not significantly different between ciprofloxacin (29/41, 71%) and imipenem (27/34, 79%). This was true for the study population and the intent-to-treat population. No differences were found in the bacterial response rate to ciprofloxacin (20/49, 49%) or imipenem (17/34, 50%) in this study population.. Despite the introduction of potent broad spectrum antimicrobial agents and the use of preventive measures, nosocomial pneumonia remains an important cause of mortality and morbidity in the ICU.1 28 29 The causative microorganism varies according to the individual patient risk profile. The severity, type, and number of risk factors and the time of onset of nosocomial pneumonia may influence the risk profiles. Gram negative bacilli, Enterobacteriaceae,H influenzae, and methicillin sensitiveS aureus are frequent causative agents in nosocomial pneumonia. P aeruginosa ...
Cimispect 500 250mg/250mg/1vial - 1Vial Injection (Imipenem and Cilastatin) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, substitutes. It is manufactured by Chandra Bhagat Pharma Pvt. Ltd.
TY - JOUR. T1 - Effect of the abscess environment on the antimicrobial activity of ciprofloxacin. AU - Bryant, Richard E.. AU - Mazza, Joyce A.. PY - 1989/11/30. Y1 - 1989/11/30. N2 - The present studies were conducted to identify factors in human purulent material that might limit or enhance the activity of ciprofloxacin against bacteria causing suppurative infection. Ciprofloxacin, imipenem, and ampicillin were tested with regard to binding or inactivation by pus. The bactericidal activity of ciprofloxacin and imipenem were tested against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, or Staphylococcus aureus in human pus with a pH of 6.0 incubated at 37°C under aerobic or anaerobic conditions. The effect of single or combination drug therapy with 20 mg/kg of ciprofloxacin, imipenem, or rifampin given every 12 hours was tested against E. coli or P. aeruginosa in polymicrobic murine abscesses that had been produced by subcutaneous injection of either of those organisms mixed ...
Cultures of the earliest isolate, JH1, and surveillance culture JH15 showed heterogeneous oxacillin resistance phenotypes when tested for population analysis profiles (PAPs). For the great majority of bacteria (>99.9%), oxacillin MICs were 0.75 μg/ml. The cultures also contained subpopulations of highly resistant cells for which oxacillin MICs were >400 μg/ml, but these subpopulations were present at a low (10−6) frequency in the cultures. A major increase in the oxacillin MICs for the majority of cells and a less heterogeneous PAP were detected in cultures of the isolates obtained next chronologically, JH2 and JH3; these isolates were recovered from the patient after a therapeutic regimen of imipenem treatment for noscomial pneumonia. Cultures of isolates recovered after this time (JH6 through JH14) showed heterogeneous oxacillin phenotypes; the MICs for the majority of cells were reduced to 1 to 3 μg/ml (Fig. 3).. Similar but much less extensive changes were also apparent with respect to ...
RODRIGUEZ, C. H. et al. Bacterial resistance to antibiotics in gram negative isolates from intensive care units: Comparative analysis between two periods (1998-2001). Medicina (B. Aires) [online]. 2003, vol.63, n.1, pp. 21-27. ISSN 1669-9106.. The incidence and drug susceptibility of gram-negative isolates from clinical samples of patients from different intensive care units at the Hospital de Clinicas José de San Martín were analysed. Two hundred isolates during the same five months period, in two different years (1998 and 2001) were obtained and evaluated. Acinetobacter spp., was the most frequently isolated microorganism. Resistance to imipenem was observed in 60% of these isolations while resistance to 3rdgeneration cephalosporin and ciprofloxacin was observed in more than 80%. Klebsiella pneumoniae was not resistant to imipenem, the resistance to 3rd and 4rth generation cephalosporins decreased from 71.4 to 30% of isolates (p,0.05), while ciprofloxacin resistance increased from 5 to 20% ...
He didnt offer his wife consolation, ciplox ear drops price particularly or apologize that they died in his care? I intelligently benadryl price always carry a few Kind Bars in my bag, because theyre a great snack made with whole foods, and have nothing artificial. 23, sporanox cost 25 There have been reports of worsening of myasthenia with the use of imipenem/cilastatin, 54 and with infusion of vancomycin. However, sporanox cost most evidence for these roles comes from in vitro, animal, and epidemiological studies, not the randomized clinical trials considered to be more definitive [ 1]! Du moins cest ainsi en milieu hospitalier, ds les centres anti douleur etc! Even effexor cost negligently less likely to feel shame upon an incident of abnormality. Jos unohdat ottaa annoksen, ota se heti kun muistat asian, jollei ole jo seuraavan annoksen aika? 7 These guidelines list observation as an option for children older than six months; observation involves deferring antibiotic treatment for 48 to ...
Based on imipenem resistance in an Acinetobacter genospecies 3 clinical isolate, we were able to identify, for the first time in this genomic species, a plasmid-encoded blaOXA-58 gene that was 100% homologous to the same ...
The IUPHAR/BPS Guide to Pharmacology. cilastatin ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
TYTU : In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with imipenem and colistin against Gram-negative bacteria ...
Drugs with less than 10 isolates are removed from the chart and from the graph. The following drugs had some data removed: quinupristin/dalfopristin, levofloxacin, tetracycline, imipenem. ...
We found a strong relationship between RF and meropenem exposure and consequently PK/PD target attainment, and we developed a graphical user tool to predict the risk of target non-attainment under meropenem standard dosing based on an ICU patients RF.. This work was focused on the analysis of the standard dosing regimen for meropenem (1000 mg administered as 30-minute infusions every 8 h) as the approved and still most frequently used dosing regimen in ICUs [12, 45]. To best represent the variety of different ICU patients, the analysis was based on extensively sampled data of a prospective observational study including a large number of patients with highly heterogeneous patient-specific factors from different ICUs, though at one single study centre.. We showed large inter-individual variability in meropenem exposure, which was in accordance with previous studies [22, 23]. The larger variability in concentrations of the late phase compared with the earlier phase of the concentration-time ...
Meropenem is an antibiotic that fights bacteria. Meropenem is used to treat severe infections of the skin or stomach. Meropenem is also used to treat bacterial meningitis (infection of brain or spinal cord). Meropenem may also be used for purposes not listed in this medication guide.
Meropenem is the name of the active ingredient in the brand name injectable antibiotic Merrem, which is used to treat serious infections caused by sus
"Cilastatin/imipenem/relebactam - AdisInsight". Springer International Publishing AG. Retrieved 29 April 2016. "FDA approves new ... used in combination with imipenem/cilastatin (Recarbrio). Vaborbactam, used in combination with meropenem (Vabomere) Bacteria ...
... whereas imipenem is usually administered as a 20-minute to one hour infusion. Meropenem is somewhat less potent than imipenem ... Imipenem, the first clinically used carbapenem, was developed at Merck and Co. It was approved for use in the United States in ... Imipenem and meropenem are useful in cases in which P. aeruginosa is a suspected pathogen. A 2015 meta analysis concluded that ... Unlike imipenem, which produced an unacceptable rate of seizures in a phase 2 trial, meropenem is effective for the treatment ...
imipenem,co-amoxiclav,clofazimine,prochlorperazine,metronidazole. On 28 December 2012, the U.S. Food and Drug Administration ( ... Chambers, H. F.; Turner, J.; Schecter, G. F.; Kawamura, M.; Hopewell, P. C. (2005). "Imipenem for Treatment of Tuberculosis in ... imipenem-cilastatin/meropenem, amikacin/streptomycin, ethionamide/prothionamide, p-aminosalicylic acid) For patients with RR-TB ...
cefepime, ceftazidime, imipenem, meropenem or piperacillin-tazobactam; plus ciprofloxacin, levofloxacin, amikacin, gentamicin, ... A third generation cephalosporin (ceftazidime) + carbapenems (imipenem) + beta lactam & beta lactamase inhibitors (piperacillin ...
Examples of carbapenems include meropenem and imipenem. "Feedback for Practical 10: Antimicrobial Agents". Archived from the ...
Susceptible to amikacin, imipenem, cefoxitin, clarithromycin and ciprofloxacin. Resistant to isoniazid and rifampin. ...
One such derivative, imipenem, was formulated in 1985. Imipenem, an N-formimidoyl derivative of thienamycin, is rapidly ... To prevent its rapid degradation, imipenem is normally coadministered with cilastatin, an inhibitor of this enzyme. Nicolaou, K ...
Imipenem/cilastatin may be an alternative *^ For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, ... Imipenem/cilastatin is an alternative, except for acute bacterial meningitis, where meropenem is preferred ...
C. histolyticum is also susceptible to metronidazole and imipenem. However, advanced gas gangrene infections caused by C. ...
Unlike imipenem, it is stable to dehydropeptidase-1, so can be given without cilastatin. In 2016, a synthetic peptide- ... The overall spectrum is similar to that of imipenem, although meropenem is more active against Enterobacteriaceae and less ... Meropenem has a reduced potential for seizures in comparison with imipenem. Several cases of severe hypokalemia have been ...
It is a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem). However, cefoxitin is a better ... coli to carbapenems such as imipenem and ertapenem. "Cefoxitin International". Drugs.com. 2 November 2020. Retrieved 8 November ... substrate than imipenem for beta-lactamases. In the presence of cefoxitin, bacteria that make beta-lactamases will increase ...
Meropenem, imipenem, and the cefoperazone-sulbactam combination (Sulperazone) are also effective. Intravenous amoxicillin- ... B. pesudomallei is generally susceptible to ceftazidime, meropenem, imipenem, and co-amoxiclav. These drugs are designed to ...
Bégué P, Quinet B, Baron S, Challier P, Fontaine JL, Lasfargues G (1989). "[Clinical and pharmacokinetic study of imipenem/ ...
Imipenem alone is an effective antibiotic and can be given without cilastatin. Cilastatin itself does not have antibiotic ... Thus imipenem/cilastatin, like amoxicillin/clavulanic acid, is a commonly used combination product. Keynan S, Hooper NM, Felici ... Dehydropeptidase is an enzyme found in the kidney and is responsible for degrading the antibiotic imipenem. Cilastatin can ... therefore be combined intravenously with imipenem in order to protect it from degradation, prolonging its antibacterial effect ...
Many studies use media with 1 to 2 mg/l of imipenem. However, bacteria that produce OXA-48 or OXA-181 result in low-level ... Therefore, more recent screening media use broth containing 0.5-1 mg/l imipenem or 0.5 mg/l ertapenem. The downsides to this ... Different drugs, such as ertapenem, imipenem, meropenem, and doripenem, belong to the class of carbapenem antibiotics. These ... each imipenem MIC doubling dilution doubled the probability of death. This classification scheme correctly predicted 82.6% of ...
Clostridia are also susceptible to tetracyclines, carbapenems (imipenem), metronidazole, vancomycin, and chloramphenicol. The ...
Cefepime, a fourth-generation cephalosporin from the β-Lactam antibiotic class.[more detail needed] Imipenem (a carbapenem) is ...
for meningitis caused by Acetobacter, as an adjunct to imipenem or colistin ...
Minocycline is usually substituted when a sulfa cannot be given; high-dose imipenem and amikacin have also been used in severe ...
... in a recent comparison of ciprofloxacin and imipenem for bacteremia involving an ESBL-producing K. pneumoniae, imipenem ... Plasmid-mediated IMP-type carbapenemases (IMP stands for active-on-imipenem), 19 varieties of which are currently known, became ... For infections caused by ESBL-producing Escherichia coli or Klebsiella species, treatment with imipenem or meropenem has been ... CcrA was known before imipenem was introduced, and producers have shown little subsequent increase. Originally described from ...
The imipenem/cilastatin, clindamycin, or combinations containing an inhibitor of beta-lactamases (i.e. Augmentin, Unasyn) are ... can be resistant to third-generation cephalosporins, but remain susceptible to imipenem, cefoxitin, and amoxicillin combined ...
Imipenem/MK-7655: Carbapenem/ β-lactamase inhibitor combination (cell wall synthesis inhibitor). In phase 2. ...
... such as Imipenem. Imipenem is a broad spectrum antibiotic produced by the bacteria Streptomyces cattleya. Ondansetron HCL ( ... Zofran) is an antiemetic often given to offset the nausea and vomiting that are a common side effect of Imipenem. Severe ...
"Refractory Craniofacial Actinomycetoma Due to Streptomyces somaliensis That Required Salvage Therapy with Amikacin and Imipenem ...
... of carbapenem antibiotics such as imipenem and meropenem have been studied in horses. However, a retrospective ... "Evaluation of the pharmacokinetics of imipenem following regional limb perfusion using the saphenous and the cephalic veins in ...
Among one set of isolates from Walter Reed Army Medical Center, 13 (35%) were susceptible to imipenem only, and two (4%) were ... Wood GC, Hanes SD, Croce MA, Fabian TC, Bougher BA (2002). "Comparison of ampicillin-sulbactam and imipenem-cilastatin for the ...
... in vitro effects of cephaloglycin and imipenem". J Am Soc Nephrol. 1 (5): 815-21. PMID 2133431. Tune B, Fravert D, Hsu C (1989 ...
Rehman, Md Tabish; Shamsi, Hira; Khan, Asad U (2014). "Insight into the Binding Mechanism of Imipenem to Human Serum Albumin by ... "A Plasmid-Borne blaOXA-58 Gene Confers Imipenem Resistance to Acinetobacter baumannii Isolates from a Lebanese Hospital". ...
In contrast to imipenem, doripenem and meropenem, it is not active against Enterococcus, Pseudomonas and Acinetobacter species ... Regarding pharmacokinetics, imipenem, doripenem and meropenem have lower plasma protein bindings (up to 25%) and shorter half- ... Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations". Therapeutic Drug Monitoring. 38 (5): 587-92. doi: ... ertapenem has slightly better activity against many Gram-negative bacteria than other carbapenems such as imipenem. ...
June 2018). "Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing ... In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio). Avibactam ...
Imipenem/cilastatin/relebactam. References[edit]. *^ a b c d e f g h "Imipenem and Cilastatin". The American Society of Health- ... Imipenem/cilastatin has the ability to kill a wide variety of bacteria. Imipenem is the active antibiotic agent and works by ... Imipenem/cilastatin was approved for use in the United States in 1985. Imipenem/cilastatin is indicated for the treatment of ... "Imipenem + Cilastatin". International Drug Price Indicator Guide. Retrieved 8 December 2016.. *^ Hamilton, Richart (2015). ...
... is a β-lactam antibiotic allergen (CHEBI:88225) imipenem (CHEBI:471744) is a carbapenems (CHEBI:46633) ... imipenem (CHEBI:471744) has role antibacterial drug (CHEBI:36047) ...
At high doses, imipenem is seizurogenic. Imipenem acts as an antimicrobial through inhibiting cell wall synthesis of various ... Not many species are resistant to imipenem except Pseudomonas aeruginosa (Oman) and Stenotrophomonas maltophilia. Imipenem is ... Imipenem was patented in 1975 and approved for medical use in 1985. It was discovered via a lengthy trial-and-error search for ... Imipenem has a broad spectrum of activity against aerobic and anaerobic, Gram-positive and Gram-negative bacteria. It is ...
Imipenem and Cilastatin Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Use imipenem and cilastatin injection until you finish the prescription, even if you feel better. If you stop using imipenem ... Before using imipenem and cilastatin injection,. *tell your doctor and pharmacist if you are allergic to imipenem or cilastatin ... Use imipenem and cilastatin injection exactly as directed. Do not use more or less of it or use it more often than prescribed ...
Imipenem, Cilastatin, and Relebactam Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... It works by preventing bacteria from destroying imipenem.. Antibiotics such as imipenem, cilastatin, and relebactam injection ... Imipenem is in a class of medications called carbapenem antibiotics. It works by killing bacteria. Cilastatin is in a class of ... Imipenem, Cilastatin, and Relebactam Injection. pronounced as (i mi pen em) (sye la stat in) (rel" e bak tam) ...
Imipenem dosage information for adults and children. Includes dosages for Bacterial Infection, Urinary Tract Infection, ... CrCl 60 to less than 90 mL/min: 750 mg (imipenem component) IV every 8 hours. -CrCl 30 to less than 60 mL/min: 500 mg (imipenem ... CrCl at least 90 mL/min: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours. -CrCl 60 to ... CrCl 30 to less than 60 mL/min: 300 mg (imipenem component) IV every 6 hours OR 500 mg (imipenem component) IV every 8 hours. - ...
... imipenem and Duration. These medicines may also interact with certain foods or diseases. ... Cilastatin / imipenem is in the drug class carbapenems.. *Cilastatin / imipenem is used to treat the following conditions: * ... cilastatin / imipenem. A total of 75 drugs are known to interact with cilastatin / imipenem. ... There were no interactions found in our database between cilastatin / imipenem and Duration - however, this does not ...
Read the side effects of Imipenem and Cilastatin as described in the medical literature. In case of any doubt consult your ... Imipenem and Cilastatin - Information. Imipenem and Cilastatin is a broad spectrum beta-lactam antibiotic, prescribed for ... Side effect(s) of Imipenem and Cilastatin Read the side effects of Imipenem and Cilastatin as described in the medical ...
Find patient medical information for imipenem-cilastatin intramuscular on WebMD including its uses, side effects and safety, ... Imipenem-Cilastatin Suspension For Reconstitution Common Brand(S): Primaxin Generic Name(S): imipenem-cilastatin View Free ... Who should not take Imipenem-Cilastatin Suspension For Reconstitution? * Does Imipenem-Cilastatin Suspension For Reconstitution ... Before using imipenem with cilastatin, tell your doctor or pharmacist if you are allergic to either of its ingredients; or to ...
Imipenem degrades easily. Studies suggest meropenem may be more stable than imipenem. However, for either antimicrobial agent, ... Imipenem and meropenem are carbapenem antimicrobial agents used to treat a variety of serious infections when an organism is ... External factors affecting imipenem performance in dried microdilution MIC plates. Journal of Clinical Microbiology 30:535-536. ... False resistance to imipenem with a microdilution susceptibility testing system. Journal of Clinical Microbiology 29:827-829. ...
Imipenem and Cilastatin for Injection. Imipenem (250 mg) + Cilastatin (250 mg). Powder, for solution. Intravenous. Pfizer. Not ... Imipenem and Cilastatin for Injection USP. Imipenem (250 mg) + Cilastatin (250 mg). Powder, for solution. Intravenous. Sandoz ... Imipenem and Cilastatin for Injection USP. Imipenem (500 mg) + Cilastatin (500 mg). Powder, for solution. Intravenous. Sandoz ... Imipenem and Cilastatin for Injection, USP. Imipenem (500 mg) + Cilastatin (500 mg). Powder, for solution. Intravenous. Mylan ...
Imipenem and Cilastatin for Injection; Imipenem and Cilastatin for Injection, USP; Primaxin; RAN-Imipenem-Cilastatin ... Imipenem and Cilastatin - Last updated on July 5, 2020. ©2020 Memorial Sloan Kettering Cancer Center. ...
J01DH51 - Imipenem and enzyme Inhibitor. Pharmaceutical companies: manufacturers, researchers, developers, local distributors ...
This article explores both national and regional trends in rates of Acinetobacter resistance to imipenem, an antibiotic often ... Eight out of nine U.S. regions showed decreased imipenem susceptibility.. *Eight regions had imipenem susceptibility of less ... This article explores both national and regional trends in rates of Acinetobacter resistance to imipenem, an antibiotic often ... Imipenem-susceptible isolates decreased from 94.1 percent of all tested isolates in 1999 to 72.4 in 2006. ...
Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae.. Poirel L1, Héritier C, Tolün V, Nordmann P ... OXA-47 had a narrow spectrum of hydrolysis activity and did not hydrolyze ceftazidime or imipenem, as is found for the beta- ... The beta-lactamase OXA-48 hydrolyzed imipenem at a high level and was remotely related (less than 46% amino acid identity) to ... It hydrolyzed penicillins and imipenem but not expanded-spectrum cephalosporins. The bla(OXA-48) gene was plasmid encoded and ...
Injectable; Injection; Cilastatin Sodium 250 mg; Imipenem 250 mg*Injectable; Injection; Cilastatin Sodium 500 mg; Imipenem 500 ... J01DH51 - Imipenem and enzyme Inhibitor. Pharmaceutical companies: manufacturers, researchers, developers, local distributors ...
Great price on Imipenem 500mg / Cilastatin 500mg solution infusion vials. FREE delivery options available. Trusted service, ... Imipenem 500mg / Cilastatin 500mg solution infusion vials. Registered UK Online Pharmacy - Prescription item. To purchase this ...
... E. ... E. Dahdouh, S. H. Shoucair, S. E. Salem, and Z. Daoud, "Mutant Prevention Concentrations of Imipenem and Meropenem against ...
Cilastatin helps imipenem work more effectively by preventing the breakdown of the antibiotic in the kidneys. Imipenem and ... Imipenem is an antibiotic that fights bacteria.. Cilastatin helps imipenem work more effectively by preventing the breakdown of ... Do not mix imipenem and cilastin with other medicines in the same syringe. ... What are the possible side effects of imipenem and cilastatin?. Get emergency medical help if you have signs of an allergic ...
Imipenem/Cilastatin Kabi Bejelentkezés szükséges. Imipenem/Cilastatin Kabi. Felhívjuk figyelmét, hogy a magyar jogszabályi ...
Imipenem Imipenem is a beta lactam antibacterial drug. Imipenem (N-formimidoylthienamycin monohydrate) is a crystalline ... For imipenem, the % time of dosing interval that unbound plasma concentrations of imipenem exceed the imipenem/relebactam ... IMIPENEM ANHYDROUS (UNII: Q20IM7HE75) (IMIPENEM ANHYDROUS - UNII:Q20IM7HE75) IMIPENEM ANHYDROUS. 500 mg in 100 mL. ... The tests conducted with imipenem, cilastatin, or imipenem/cilastatin included: V79 mammalian cell mutagenesis assay (imipenem ...
Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia. The safety and scientific validity of this ... Drug: Imipenem Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of ... Drug: Imipenem Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr ... To determine plasma Imipenem PK/PD parameters (the PK/PD index (T,MIC), the probability of target attainment (PTA) at 40% (T, ...
Exposure for 10 h to 20 x MIC imipenem and 15 x MIC tobramycin reduced the number of viable immobilized bacteria to 0.3% and 3 ... Imipenem / pharmacology*. Microbial Sensitivity Tests. Pseudomonas aeruginosa / drug effects*, growth & development. ... Effective diffusivity measurements showed that the diffusion of imipenem in the alginate layer was not hindered. A slight but ... 0/Anti-Bacterial Agents; 0/Thienamycins; 32986-56-4/Tobramycin; 74431-23-5/Imipenem; EC 3.5.2.6/beta-Lactamases ...
Only one patient developed a seizure while on imipenem/cilastatin. Conclusion: The prescription of imipenem/cilastatin at our ... who were not started on imipenem/cilastatin empirically inappropriately received imipenem/cilastatin post-culture results. ... The patients received imipenem/cilastatin mainly for urinary tract infections (27%) or for sepsis of an unknown focus (22%). ... The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The ...
Imipenem and Sulbactam in the Treatment of Imipenem-resistant Acinetobacter Baumannii Bacteremia. The safety and scientific ... Effectiveness of Imipenem and Sulbactam in the Treatment of Bacteremic Patients Contracted With Imipenem-resistant ... Imipenem. Sulbactam. Anti-Bacterial Agents. Anti-Infective Agents. beta-Lactamase Inhibitors. Enzyme Inhibitors. Molecular ... Infections caused by imipenem-resistant Acinetobacter baumannii are associated with high mortality and morbidity. The treatment ...
6B92 isolated from the blood culture of a patient at the Edinburgh Royal Infirmary i 1985 was found to be resistant to imipenem ... ARI 1: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii Int J Antimicrob Agents. 1993 Feb;2(2):81-7. doi ... Acinetobacter resistant to imipenem). Despite the fact that original clinical isolate could be cured of its resistance to ... ampicillin and cephaloridine slowly during enzyme assay but inactivation of imipenem could only be demonstrated by ...
Learn more about Recarbrio (Imipenem, Cilastatin, And Relebactam) at EverydayHealth.com. ... Imipenem, Cilastatin, And Relebactam), including what it is used for, warnings, reviews, side effects, and interactions. ... What should I do if I missed a dose of Recarbrio (Imipenem, Cilastatin, And Relebactam)?. If you receive imipenem, cilastatin, ... How to take Recarbrio (Imipenem, Cilastatin, And Relebactam)?. Use Recarbrio (Imipenem, Cilastatin, And Relebactam) exactly as ...
Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability ... Biological activities of biapenem, imipenem, and meropenem were compared with respect to permeability into Gram-negative ... from Bacteroides fragilis and Xanthomonas maltophilia hydrolyzing biapenem at lower Vmax values than meropenem or imipenem. In ...
Structural Basis for Imipenem Inhibition of Class C beta-lactamases. Beadle, B.M., Shoichet, B.K.. (2002) Antimicrob Agents ... To determine how imipenem inhibits the class C beta-lactamase AmpC, the X-ray crystal structure of the acyl-enzyme complex was ... To determine how imipenem inhibits the class C beta-lactamase AmpC, the X-ray crystal structure of the acyl-enzyme complex was ... X-ray crystal structure of AmpC WT beta-lactamase in complex with covalently bound imipenem. *DOI: 10.2210/pdb1LL5/pdb ...
  • Imipenem/cilastatin , sold under the brand name Primaxin among others, is an antibiotic useful for the treatment of a number of bacterial infections . (wikipedia.org)
  • Imipenem (trade name Primaxin among others) is an intravenous β-lactam antibiotic discovered by Merck scientists Burton Christensen, William Leanza, and Kenneth Wildonger in the mid-1970s. (wikipedia.org)
  • Cell walls in growing bacteria are always being synthesized, so song of ice and fire 4 pdf Imipenem/cilastatin (marketed as Primaxin in the USA, and as Cilasafe in India) is an antibiotic useful for the treatment of a number of bacterial infections. (theluckettsfair.com)
  • Drug Name : Imipenem and Cilastatin Imipenem and Cilastatin (Primaxin) generic is a … Imipenem/cilastatin is indicated for the treatment of severe or complicated skin, tissue, joint, respiratory tract, intra-abdominal, urinary tract and urogenital infections, but not meningitis (as it does not pass through the blood brain barrier), endocarditis, and sepsis due to susceptible organisms. (bradtechguy.com)
  • Imipenem/cilastatin (Brand name: Primaxin) Doripenem (Brand name: Doribax) Meropenem (Brand name: Merrem) Ertapenem (Brand name: Invanz) Contents. (bradtechguy.com)
  • The first carbapenem, imipenem-cilastatin (Primaxin), is a chemically stable analogue of thienamycin produced by Streptomyces cattleya. (alpfmedical.info)
  • Chemically, Imipenem (also known as Primaxin) is a semisynthetic thienamycin (β-lactam antibiotic also known as carbapenem-type antibiotic) with a broad spectrum antibacterial activity. (drugsdetails.com)
  • Several instances of cholestatic jaundice arising during or shortly after therapy have been reported with imipenem-cilastatin and other carbapenems. (wikipedia.org)
  • Imipenem and other carbapenems have not been linked to cases of acute liver failure. (wikipedia.org)
  • The cholestatic hepatitis attributed to imipenem-cilastatin and the carbapenems is probably immunoallergic and resembles the rare, clinically apparent liver injury that has been linked to penicillins and cephalosporins. (wikipedia.org)
  • The imipenem resistant isolates identified were subsequently tested against other carbapenems (meropenem and ertapenem) and also against rifampin, clindamycin, chloramphenicol, tetracycline, and tigecycline. (cdc.gov)
  • Cilastatin / imipenem is in the drug class carbapenems . (drugs.com)
  • Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. (drugbank.ca)
  • Metallo-beta-lactamases hydrolysed the carbapenems at measurable rates, with enzymes from Bacteroides fragilis and Xanthomonas maltophilia hydrolyzing biapenem at lower Vmax values than meropenem or imipenem. (nih.gov)
  • Although carbapenems, such as imipenem and meropenem, remain effective at treating serious multidrug-resistant P. aeruginosa infections, a rise in carbapenem resistance among isolates has been reported worldwide ( 2 ). (asm.org)
  • Richerson MA, Ambrose PG, Quintiliani R, Nightingale CH: Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem. (lgmpharma.com)
  • The longest established carbapenems are imipenem, meropenem and ertapenem, while more recently developed examples include doripenem, biapenem, panipenem, razupenem and tomopenem [ 4 ]. (mdpi.com)
  • In the study we tested drug sensitivity to 3 carbapenems (doripenem, imipenem and meropenem) of Gram-negative clinical isolates from Southern Poland.Material and methods. (edu.pl)
  • Imipenem and cilastatin injection is used to treat certain serious infections that are caused by bacteria, including endocarditis (infection of the heart lining and valves) and respiratory tract (including pneumonia), urinary tract, abdominal (stomach area), gynecological, blood, skin, bone, and joint infections. (medlineplus.gov)
  • Antibiotics such as imipenem and cilastatin injection will not work for colds, flu, or other viral infections. (medlineplus.gov)
  • Imipenem and cilastatin injection comes as a powder to be mixed with liquid to be injected intravenously (into a vein) or intramuscularly (into a muscle). (medlineplus.gov)
  • Your doctor will tell you how long to use imipenem and cilastatin injection. (medlineplus.gov)
  • You may receive imipenem and cilastatin injection in a hospital, or you may administer the medication at home. (medlineplus.gov)
  • If you are using imipenem and cilastatin injection at home, use it at around the same times every day. (medlineplus.gov)
  • Use imipenem and cilastatin injection exactly as directed. (medlineplus.gov)
  • If you will be using imipenem and cilastatin injection at home, your healthcare provider will show you how to use the medication. (medlineplus.gov)
  • Ask your healthcare provider what to do if you have any problems injecting imipenem and cilastatin injection. (medlineplus.gov)
  • You should begin to feel better during the first few days of treatment with imipenem and cilastatin injection. (medlineplus.gov)
  • Use imipenem and cilastatin injection until you finish the prescription, even if you feel better. (medlineplus.gov)
  • If you stop using imipenem and cilastatin injection too soon or if you skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics. (medlineplus.gov)
  • Imipenem and cilastatin injection is also sometimes used to treat patients who have fever and are at high risk for infection because they have a low number of white blood cells. (medlineplus.gov)
  • or any of the ingredients in imipenem and cilastatin injection. (medlineplus.gov)
  • Imipenem, cilastatin, and relebactam injection is used to treat adults with certain serious urinary tract infections including kidney infections, and certain serious abdominal (stomach) infections when there are few or no other treatment options. (medlineplus.gov)
  • Imipenem, cilastatin, and relebactam injection may cause side effects. (medlineplus.gov)
  • RECARBRIO 1.25 grams for injection is supplied as sterile powder for constitution in a single-dose vial containing imipenem 500 mg (anhydrate equivalent), cilastatin 500 mg (free acid equivalent), and relebactam 250 mg (anhydrate equivalent). (nih.gov)
  • Imipenem/cilastatin is for injection into a muscle or infusion into a vein. (prescriptiongiant.com)
  • Bioavailability after IM injection is approximately 95% for imipenem and 75% for cilastatin. (elephantcare.org)
  • Imipenem/Cilastatin is usually given as an injection at your doctor's office, hospital, or clinic. (drugster.info)
  • Please select more than one item to compare Descriptions Imipenem, cilastatin, and relebactam combination injection is used to treat complicated bacterial infections in many different parts of the body (eg, kidneys, stomach). (bradtechguy.com)
  • Intravenous: 250mg imipenem, 250mg cilastatin, and 10mg sodium bicarbonate power mixture for intravenous injection. (bradtechguy.com)
  • The dosage recommendations for Imipenem/ Cilastatin Injection represent the quantity of Imipenem to be administered. (saviorlifetec.com.tw)
  • The total daily dosage for Imipenem/ Cilastatin Injection should be based on the type or severity of infection and given in equally divided doses based on consideration of degree of susceptibility of the pathogen(s), renal function, and body weight. (saviorlifetec.com.tw)
  • The considered drug "Imipenem + Cilastatin" is available in the form of powder for injection( for intravenous administration) in vials of various sizes, namely: sixty and one hundred twenty milliliters. (behealthiers.com)
  • In cases where the drug is prescribed for intramuscular injection, vials containing 0.5 or 0.75 grams of imipenem and cilastatin should be purchased( depending on the dosage that has been prescribed to the patient by the attending physician). (behealthiers.com)
  • Imipenem-Cilastatin Injection is a medicine that is used for the treatment of Bacterial Infections, Infections During Or After Delivery Management Of Fever, Patients With Reduced Immunity Due To Low White Blood Cells and other conditions. (salvavidaspharmaceutical.com)
  • Imipenem-Cilastatin Injection contains Cilastatin, and Imipenem as active ingredients. (salvavidaspharmaceutical.com)
  • The following is a list of possible side effects that may occur from all constituting ingredients of Imipenem-Cilastatin Injection. (salvavidaspharmaceutical.com)
  • Imipenem And Cilastatin For Injection IP is carefully formulated and processed by well quality medical professionals in line with pharmaceutical industry norms, and using the best in grade chemical compounds that guarantee its the best result and good shelf life. (gethealpharma.com)
  • Ideal for IV use only, the Imipenem And Cilastatin For Injection IP is effective to treat definite serious infections caused by bacteria, comprising infection of the heart lining & valves and respiratory tract, urinary tract, abdominal gynecological, skin, blood, joint, and bone, infections. (gethealpharma.com)
  • Imipenem And Cilastatin Injection IP can be procured from various sizes and specifications. (broadinjectables.co.in)
  • Imipenem And Cilastatin Injection IP aids to reduce the chances of severe bacteria in the body. (broadinjectables.co.in)
  • There was a more than 300 percent increase in the proportion of Acinetobacter cases resistant to the antibiotic imipenem during 1999 to 2006. (rwjf.org)
  • Imipenem is an antibiotic that fights bacteria. (wellspan.org)
  • Cilastatin helps imipenem work more effectively by preventing the breakdown of the antibiotic in the kidneys. (wellspan.org)
  • Exposure for 10 h to 20 x MIC imipenem and 15 x MIC tobramycin reduced the number of viable immobilized bacteria to 0.3% and 3%, respectively, of the initial cell population, whereas these antibiotic concentrations were much more efficient (bactericidal) against free-cell cultures (5 log kill in 6 h). (biomedsearch.com)
  • Imipenem is one of the strongest antibiotics now available for treating VAP which is associated with gram-negative and gram-positive bacteria, and it belongs to beta-lactam antibiotic group (carbapenem). (pubmedcentralcanada.ca)
  • Chemistry - Imipenem monohydrate is a carbapenem antibiotic that occurs as white or off-white, non-hygroscopic, crystalline compound. (elephantcare.org)
  • Pharmacology - This fixed combination of a carbapenem antibiotic (imipenem) and an inhibitor (cilastatin) of dehydropeptidase I (DHP I) has a very broad spectrum of activity. (elephantcare.org)
  • Imipenem/Cilastatin is a carbapenem antibiotic. (drugster.info)
  • Imipenem is a beta-lactam antibiotic that has a wide spectrum of activity against gram negative and gram positive organisms and is commonly used in an ICU setting. (blogspot.com)
  • Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a fixed-dose combination medication used as an antibiotic. (bradtechguy.com)
  • Imipenem is the active antibiotic agent and works by interfering with their ability to form cell walls, so the bacteria break up and die. (bradtechguy.com)
  • Continue Learning about Antibiotic 6 Ailments That Call for an Antibiotic [5][6], Patients who are allergic to penicillin, cephalosporins, and related drugs may react to imipenem. (bradtechguy.com)
  • Pastel DA: Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination. (lgmpharma.com)
  • Our results indicate that exposure to subinhibitory concentrations of imipenem can stimulate biofilm formation and induce iron uptake in a pathogenic strain of A. baumannii , with potential implications on antibiotic susceptibility and ability to persist in the human host. (biomedcentral.com)
  • The composition of the preparation "Imipenem + Cilastatin" includes an equal combination of cilastatin( which is an inhibitor of the enzyme dihydropeptidase of the kidneys) and sodium salts of imipenem( antibiotic).In one bottle of the drug, as a rule, contains five hundred milligrams of both substances. (behealthiers.com)
  • The first, imipenem, is a special beta-lactam antibiotic that actively destroyspathogenic bacteria( thus having a bactericidal effect).This substance has a rather wide spectrum of action. (behealthiers.com)
  • The second component, cilastatin sodium, actively affecting the enzyme, which decomposes imipenem in the kidneys of the patient's body, suppresses its action, which contributes to a sufficient increase in the concentration of the above antibiotic in the unchanged form in the patient's body. (behealthiers.com)
  • As a conclusion-doripenem, which has high in vitro activity (almost the same as imipenem and meropenem) as well as beneficial pharmacologic properties, may be an alternative solution in the treatment of multiresistant Gram-negative bacteria, especially in patients in severe status who require restrictive antibiotic regimens. (edu.pl)
  • Using data from 300 hospitals around the country, this analysis looked at 47,415 Acinetobacter species isolates and their susceptibility against imipenem over the period 1999 to 2006. (rwjf.org)
  • E. Dahdouh, S. H. Shoucair, S. E. Salem, and Z. Daoud, "Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii ," The Scientific World Journal , vol. 2014, Article ID 979648, 7 pages, 2014. (hindawi.com)
  • Infections caused by imipenem-resistant Acinetobacter baumannii are associated with high mortality and morbidity. (clinicaltrials.gov)
  • A strain of Acinetobacter baumannii 6B92 isolated from the blood culture of a patient at the Edinburgh Royal Infirmary i 1985 was found to be resistant to imipenem, all classes of cephalosporins and penicillins. (nih.gov)
  • pI 9.0) and a novel beta-lactomase of pI 6.65 named ARI 1 (Acinetobacter resistant to imipenem). (nih.gov)
  • A total of 342 imipenem-resistant Acinetobacter baumannii isolates (IRABs) were collected from 16 Chinese cities. (asm.org)
  • The study was performed to determine the consumption of imipenem and resistance of gram-negative pathogens (Pseudomonas aeruginosa, Acinetobacter sp. (srce.hr)
  • Imipenem resistance of Acinetobacter sp. (srce.hr)
  • Results suggest that the consumption of imipenem might lead to changes in resistance to imipenem among Acinetobacter strains. (srce.hr)
  • Increase of Ceftazidime- and Fluoroquinolone-Resistant Klebsiella pneumoniae and Imipenem-Resistant Acinetobacter spp. (pubmedcentralcanada.ca)
  • A gradual increase of vancomycin-resistant Enterococcus faecium and imipenem-resistant Acinetobacter spp. (pubmedcentralcanada.ca)
  • remain prevalent in Korea, while the incidence of vancomycin-resistant E. faecium and imipenem-resistant Acinetobacter spp. (pubmedcentralcanada.ca)
  • Imipenem-resistant Acinetobacter baumannii (IRAB) is an important cause of hospital-acquired infection. (biomedcentral.com)
  • Objective To observe and compare the clinical efficacy of tigecyclinc combined with imipenem/cilastation,imipenem/cilastation combined with cefoperazone sulbacta,prolonging intravenous infusion of imipenem/cilastatin combined with cefoperazone sulbactam on severe pan-resistance Acinetobacter baumannii. (cnki.com.cn)
  • 05). Conclusion 3 hours of Imipenem/cilastatin infusion can improve the efficacy in treatment of severe pan-resistant patients with Acinetobacter baumannii infection,and it is suitable for applying to clinical treatment. (cnki.com.cn)
  • Administer RECARBRIO 1.25 grams (imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg) by intravenous (IV) infusion over 30 minutes every 6 hours in patients 18 years of age and older with creatinine clearance (CLcr) 90 mL/min or greater. (nih.gov)
  • Imipenem, cilastatin, and relebactam is a combination medicine that is used to treat complicated infections of the urinary tract (bladder and kidneys) or infections within the stomach area (abdomen). (everydayhealth.com)
  • Imipenem, cilastatin, and relebactam is also used to treat pneumonia (a lung infection) caused by being in a hospital or using a ventilator. (everydayhealth.com)
  • What is Recarbrio (Imipenem, Cilastatin, And Relebactam) used for? (everydayhealth.com)
  • You should not be treated with this medicine if you are allergic to imipenem, cilastatin, or relebactam. (everydayhealth.com)
  • Can I take Recarbrio (Imipenem, Cilastatin, And Relebactam) if I'm pregnant or breastfeeding? (everydayhealth.com)
  • Use Recarbrio (Imipenem, Cilastatin, And Relebactam) exactly as directed on the label, or as prescribed by your doctor. (everydayhealth.com)
  • Imipenem, cilastatin, and relebactam will not treat a viral infection such as the flu or a common cold. (everydayhealth.com)
  • If you receive imipenem, cilastatin, and relebactam in a clinical setting, you are not likely to miss a dose. (everydayhealth.com)
  • We evaluated the ability of relebactam to restore imipenem susceptibility against a collection of Klebsiella pneumoniae isolates from Greek hospitals. (springer.com)
  • Imipenem-relebactam MICs were interpreted using the breakpoints proposed for imipenem. (springer.com)
  • 64 mg/L). Reduced activity of imipenem-relebactam was rarely detected (2%) and was associated with chromosomal factors ( ompK35 disruption and/or mutated ompK36 ). (springer.com)
  • Only ceftazidime-avibactam showed in vitro activity comparable to imipenem-relebactam (99.6% susceptible). (springer.com)
  • Relebactam provided only weak potentiation of imipenem activity against K. pneumoniae with class D OXA-48-like enzymes. (springer.com)
  • Imipenem/relebactam is a topic covered in the Johns Hopkins ABX Guide . (hopkinsguides.com)
  • Johns Hopkins Guide , www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540727/7/Imipenem_relebactam. (hopkinsguides.com)
  • Avdic E. Imipenem/relebactam. (hopkinsguides.com)
  • Pediatrics Central , peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540727/all/Imipenem_relebactam. (unboundmedicine.com)
  • Emergency Central , emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110615/all/imipenem_cilastatin_relebactam. (unboundmedicine.com)
  • Vallerand AHA, Sanoski CAC, Quiring CC. Imipenem/cilastatin/relebactam. (unboundmedicine.com)
  • In the HABP/VABP trial (Trial 1), patients were treated with either RECARBRIO™ (imipenem, cilastatin, and relebactam) or piperacillin and tazobactam (4.5 grams). (merckconnect.com)
  • In the cUTI trial (Trial 2) and cIAI trial (Trial 3), patients in the treatment arms were treated with either imipenem 500 mg/cilastatin 500 mg and relebactam 250 mg or imipenem 500 mg/cilastatin 500 mg and relebactam 125 mg (not an approved dose), and patients in the control arm were treated with imipenem 500 mg/cilastatin 500 mg plus placebo (IV normal saline). (merckconnect.com)
  • Across Trials 2 and 3, the mean duration of IV therapy in patients treated with imipenem/cilastatin plus relebactam 250 mg was approximately 7 days. (merckconnect.com)
  • Trial 2 included 198 adult patients treated with imipenem/cilastatin and relebactam (99 patients each with imipenem 500 mg/cilastatin 500 mg plus relebactam 125 mg or relebactam 250 mg) and 100 patients treated with imipenem 500 mg/cilastatin 500 mg, administered intravenously over 30 minutes every 6 hours. (merckconnect.com)
  • Trial 3 included 233 adult patients treated with imipenem/cilastatin plus relebactam (116 subjects with imipenem 500 mg/cilastatin 500 mg and relebactam 125 mg and 117 subjects with imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg), and 114 patients treated with imipenem 500 mg/cilastatin 500 mg, administered intravenously over 30 minutes every 6 hours for 4 to 14 days, at the discretion of the investigator. (merckconnect.com)
  • Adverse reactions leading to discontinuation occurred in 5.6% (15/266) of patients receiving imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg and 8.2% (22/269) of patients receiving piperacillin and tazobactam. (merckconnect.com)
  • In Trials 2 and 3, serious adverse reactions occurred in 3.2% (7/216) of patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg and 5.1% (11/214) of patients receiving imipenem 500 mg/cilastatin 500 mg. (merckconnect.com)
  • There were no deaths reported in patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg or imipenem 500 mg/cilastatin 500 mg alone. (merckconnect.com)
  • Deaths were reported in 1.4% (3/215) of patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 125 mg (not an approved dose). (merckconnect.com)
  • Clavulanic acid or clavulanate, usually combined with amoxicillin (Augmentin) or ticarcillin (Timentin) Sulbactam, usually combined with ampicillin (Unasyn) or cefoperazone (Sulperazon) Tazobactam, usually combined with piperacillin (Zosyn and Tazocin) β-lactamase inhibitors without a β-lactam core: Avibactam, approved in combination with ceftazidime (Avycaz), currently undergoing clinical trials for combination with ceftaroline Relebactam, used in combination with imipenem/cilastatin (Recarbrio). (wikipedia.org)
  • Seizures and Central Nervous System Adverse Reactions: CNS adverse reactions such as seizures have been reported with imipenem/cilastatin, a component of RECARBRIO. (nih.gov)
  • Imipenem spectrum of bacterial susceptibility and Resistance" (PDF). (wikipedia.org)
  • A group of 191 strains isolated during 2012-2015 from 15 Portuguese hospitals ( 1 ) were tested for imipenem susceptibility. (cdc.gov)
  • Eight out of nine U.S. regions showed decreased imipenem susceptibility. (rwjf.org)
  • Eight regions had imipenem susceptibility of less than 85 percent by 2006. (rwjf.org)
  • Overall, the East South Central region was the only region not showing a significant decrease in imipenem susceptibility. (rwjf.org)
  • Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels. (asm.org)
  • Radiometer America Inc., Westlake, Ohio), imipenem susceptibility declined from 70 to 44% for clinical isolates of Pseudomonas aeruginosa. (asm.org)
  • Subsequent evaluations with P. aeruginosa ATCC 27853 revealed a similar susceptibility pattern and an increase in the MIC of imipenem when determined in panels with increasing ages. (asm.org)
  • These data suggest that imipenem in Sensititre MIC and breakpoint panels degrades over time and that the decrease in imipenem may be largely responsible for the decline in P. aeruginosa susceptibility. (asm.org)
  • Although imipenem has in vitro activity against Enterococcus faecalis and Food and Drug Administration-approved indications for treatment of infections caused by this microorganism, there are no NCCLS guidelines for susceptibility testing of imipenem versus enterococci. (eurekamag.com)
  • The susceptibility of isolates to penicillin or ampicillin accurately predicted the in vitro activity of imipenem. (eurekamag.com)
  • Since the susceptibility of enterococci to imipenem can be predicted by the results obtained by testing of penicillin or ampicillin, testing of imipenem by clinical laboratories probably is not necessary. (eurekamag.com)
  • Susceptibility testing and Minimum Inhibitory Concentrations (MICs) of meropenem, imipenem and piperacillin/tazobactam were determined locally by Etest method. (biomedcentral.com)
  • Susceptibility to meropenem was confirmed at a central laboratory by disc diffusion method and MICs determined by agar dilution method for meropenem, imipenem and piperacillin/tazobactam. (biomedcentral.com)
  • Both cefoxitin and imipenem have been used successfully, but susceptibility is variable. (medscape.com)
  • Imipenem/cilastatin is used for lower respiratory tract infections , urinary tract infections , intra-abdominal infections, gynecologic infections, bacterial sepsis , bone and joint infections, skin and skin structure infections, endocarditis and polymicrobic infections. (wikipedia.org)
  • Imipenem and meropenem are carbapenem antimicrobial agents used to treat a variety of serious infections when an organism is resistant to the primary agent of choice. (cdc.gov)
  • Imipenem and cilastatin is a combination medicine used to treat severe infections of the lower respiratory tract, skin, stomach, or female reproductive organs. (wellspan.org)
  • In a pan-European study of ≈900 C. difficile strains, the overall rate of resistance to imipenem, an antimicrobial drug of the carbapenem class, currently widely used as a last-line drug to treat infections by gram-negative bacteria, was found to be 7.41%, and the geometric mean (GM) MIC of imipenem for RT017 strains was 5.91 mg/L ( 8 ). (cdc.gov)
  • Adult: IV- Susceptible infections- As imipenem: 1-2 g/day in divided doses 6-8 hourly. (medindia.net)
  • IM- Susceptible infections- As imipenem: 500 or 750 mg 12 hourly. (medindia.net)
  • Ciprofloxacin and imipenem are two broad spectrum antimicrobial agents of different chemical class that have been widely investigated separately for the treatment of lower respiratory tract infections. (bmj.com)
  • Imipenem kills or stops the growth of bacteria that cause severe infections. (prescriptiongiant.com)
  • Imipenem/cilastatin is usually given in a hospital or clinic for severe infections. (prescriptiongiant.com)
  • Our results suggest that β-lactam antibiotics should be used with caution in patients with imipenem-resistant ceftazidime-susceptible P. aeruginosa infection, especially in high-inoculum infections such as endocarditis and osteomyelitis. (asm.org)
  • Uses/Indications - Imipenem may be useful in equine or small animal medicine to treat serious infections when other less expensive antibiotics are ineffective or have unacceptable adverse effect profiles. (elephantcare.org)
  • The major objective of the present study was to assess the in vitro activity of meropenem compared to imipenem and piperacillin/tazobactam, against 1071 non-repetitive isolates collected from patients with bacteremia (55%), pneumonia (29%), peritonitis (12%) and wound infections (3%), in 15 French hospitals in 2006. (biomedcentral.com)
  • In an open, controlled, randomized study the safety and efficacy of imipenem/cilastatin was compared with that of the combination cefotaxime/gentamicin (plus metronidazole in patients with suspected anaerobe infection) in the treatment of 337 patients from 12 German and 5 Austrian centers who had non-life-threatening infections. (theluckettsfair.com)
  • In an open randomised multicentre trial the efficacy (clinical and bacteriological) and safety of empirical monotherapy with meropenem (MEM: 1 g every 8 h, iv) have been compared with imipenem/cilastatin (IMI: 1 g every 8 h, iv) in patients with serious bacterial infections at one or more of the following sites: systemic, intra-abdominal and lower respiratory tract infections. (biomedcentral.com)
  • Raouf MR, Sayed M, Rizk HA, Hassuna NA (2018) High incidence of MBL-mediated imipenem resistance among Pseudomonas aeruginosa from surgical site infections in Egypt. (jidc.org)
  • Imipenem-cilastatin is one of the drugs of first choice for the empirical therapy of many polymicrobial pulmonary, intraabdominal, and soft tissue infections. (alpfmedical.info)
  • The combination of imipenem and cilastatin is for treatment of multiple organism infections in which other agents do not have wide-spectrum coverage or are contraindicated due to potential for toxicity. (medscape.com)
  • Alternative to imipenem for severe Enterobacter infections. (medscape.com)
  • When the incidence of MRSA is low, imipenem-cilastatin, meropenem and piperacillin-tazobactam 3.375 g q6h would be optimal choices for the empiric treatment of complicated skin and soft tissue infections among the regimens studied. (qxmd.com)
  • Dual drug delivery of vancomycin and imipenem/cilastatin by coaxial nanofibers for treatment of diabetic foot ulcer infections. (bvsalud.org)
  • Not many species are resistant to imipenem except Pseudomonas aeruginosa (Oman) and Stenotrophomonas maltophilia. (wikipedia.org)
  • What Gram-negative organisms are resistant to imipenem and/or meropenem? (cdc.gov)
  • Stenotrophomonas maltophilia isolates are intrinsically resistant to imipenem. (cdc.gov)
  • Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. (dovepress.com)
  • In this study, we investigated the prevalence of imipenem-resistant A. baumannii isolates (IRABs) in China and characterized the genes of the carbapenemases in IRABs. (asm.org)
  • All isolates were found to be resistant to imipenem and meropenem. (asm.org)
  • We describe imipenem-resistant and imipenem-susceptible clinical isolates of Clostridium difficile ribotype 017 in Portugal. (cdc.gov)
  • All ribotype 017 isolates carried an extra penicillin-binding protein gene, pbp5 , and the imipenem-resistant isolates had additional substitutions near the transpeptidase active sites of pbp1 and pbp3 . (cdc.gov)
  • We found 24 (12.6%) were resistant to imipenem. (cdc.gov)
  • the MIC for the 2 non-RT017 isolates was 16 mg/L. The 22 imipenem-resistant RT017 isolates were found at hospital A throughout the study period, suggesting the existence of a persistent clone, a finding supported by whole-genome sequencing data ( Technical Appendix ). (cdc.gov)
  • This study has been undertaken for determining the presence of the bla NDM-1 gene among the clinical isolates of imipenem-resistant Gram-negative bacteria in a tertiary care center in Dharan, Nepal. (hindawi.com)
  • A total of 75 imipenem-resistant Gram-negative isolates were studied. (hindawi.com)
  • A high percentage of the NDM-1 producer was noted among imipenem-resistant GNB. (hindawi.com)
  • The susceptible and resistant pairs were recovered from multiple sources (including sputum, blood, and urine) from patients treated with various doses of imipenem (n = 15), norfloxacin (n = 6), and ciprofloxacin (n = 4). (nih.gov)
  • Genome mining of cyslabdan-producing Streptomyces cyslabdanicus K04-0144 revealed that a set of four genes, cldA , cldB , cldC , and cldD (the cld cluster), which formed a single transcriptional unit, were involved in the biosynthesis of cyslabdan that potentiates imipenem activity against methicillin-resistant Staphylococcus aureus . (springer.com)
  • We studied the resistance mechanism and antimicrobial effects of β-lactams on imipenem-resistant Pseudomonas aeruginosa isolates that were susceptible to ceftazidime as detected by time-kill curve methods. (asm.org)
  • Among 215 P. aeruginosa isolates from hospitalized patients in eight hospitals in the Republic of Korea, 18 isolates (23.4% of 77 imipenem-resistant isolates) were imipenem resistant and ceftazidime susceptible. (asm.org)
  • All 18 imipenem-resistant ceftazidime-susceptible isolates showed decreased mRNA expression of oprD , and overexpression of mexB was observed in 13 isolates. (asm.org)
  • Time-kill curve methods were applied to three selected imipenem-resistant ceftazidime-susceptible isolates at a standard inoculum (5 × 10 5 CFU/ml) or at a high inoculum (5 × 10 7 CFU/ml) to evaluate the antimicrobial effects of β-lactams. (asm.org)
  • Higher incidences of third-generation cephalosporin-resistant E. coli and K. pneumoniae and imipenem-resistant P. aeruginosa were found in the commercial laboratory than in the hospitals. (pubmedcentralcanada.ca)
  • The higher prevalences of third-generation cephalosporin-resistant E. coli and K. pneumoniae , and imipenem-resistant P. aeruginosa in the commercial laboratory are a new concern. (pubmedcentralcanada.ca)
  • All isolates were resistant to imipenem. (biomedcentral.com)
  • The main objective of this work was to evaluate for the first time in Minia- Upper Egypt, the incidence of imipenem-resistant Pseudomonas aeruginosa infection of surgical wounds particularly that mediated by MBL production. (jidc.org)
  • The prevalence of MBL-producing isolates among Imipenem-resistant P. aeruginosa (IRPA) was 85 % by phenotypic method with 29% of them harboring bla VIM gene. (jidc.org)
  • Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a KONSAR study in 2002. (semanticscholar.org)
  • article{Lee2004IncreasingPO, title={Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a KONSAR study in 2002. (semanticscholar.org)
  • An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. (semanticscholar.org)
  • Organisms resistant to imipenem include E. faecium, Stenotrophomonas mal-tophilia, and MRSA . (alpfmedical.info)
  • Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin. (biomedsearch.com)
  • Imipenem has activity against a wide variety of bacteria, including Gram-positive aerobic cocci (including some bacteriostatic activity against enterococci), Gram-positive aerobic bacilli (including static activity against Listeria ), Gram-negative aerobic bacteria (H aemophilus, Enterobacteriaceae , many strains of Pseudomonas aeruginosa ), and anaerobes (including some strains of Bacteroides ). (elephantcare.org)
  • Compared to imipenem, meropenem displays lower MICs against Enterobacteriaceae , Escherichia coli and Pseudomonas aeruginosa . (biomedcentral.com)
  • Imipenem resistance was found in 28.57% of the isolated Pseudomonas aeruginosa . (jidc.org)
  • In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b. (drugbank.ca)
  • In the majority of pairs studied, failure to eradicate P. aeruginosa after therapy with imipenem, norfloxacin, and ciprofloxacin was due to the development of resistance rather than to reinfection. (nih.gov)
  • Rates of imipenem resistance in P. aeruginosa showed a time course similar to rate of consumption. (neli.org.uk)
  • Read "In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin againstPseudomonas aeruginosa, European Journal of Clinical Microbiology Infectious Diseases" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. (theluckettsfair.com)
  • When compared with the in vitro activities of third-generation cephalosporins, imipenem is more potent against E. faecalis, B. fragilis, and P. aeruginosa. (alpfmedical.info)
  • The epileptogenic activity of imipenem in rats with experimentally induced hypovolaemia or endotoxaemia was investigated by pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect. (ovid.com)
  • BACKGROUND A prospective multicentre study was undertaken to compare the efficacy of intravenous ciprofloxacin or imipenem in the treatment of severe nosocomial pneumonia requiring mechanical ventilation. (bmj.com)
  • Methods 36 patients with severe pulmonary infection were randomly divided into trial group 1,2 and 3 with each group of 12 patients and ticyclinc combined with imipenem/cilastatin,imipenem/cilastatin combined with cefoperazone sulbactam,imipenem/cilastatin with prolonged intravenous infusion time combined with cephalosporins Paclitaxel were given each of these 3 groups respectively( P 0. (cnki.com.cn)
  • In a double-blind, multicenter trial, 541 febrile granulocytopenic patients were randomized to receive either intravenous (iv) clinafloxacin (200 mg every 12 h) or iv imipenem (500 mg every 6 h) as empirical monotherapy. (oup.com)
  • Imipenem and Cilastatin sodium (Sterile Bulk) is a potent broad-spectrum antibacterial agent for intravenous infusion. (saviorlifetec.com.tw)
  • Imipenem-cilastatin is only available for intramuscular or intravenous administration because oral bioavailability is poor. (alpfmedical.info)
  • How much resistance to imipenem or meropenem occurs in clinical isolates? (cdc.gov)
  • The major objective of the present study was to assess the in vitro activity of meropenem which has been recently re-introduced in French hospitals, compared to imipenem and piperacillin/tazobactam, against clinical isolates included in the spectrum of meropenem. (biomedcentral.com)
  • 32 mg/L) at 48 h of growth but not at 24 h for most susceptible strains, MICs of imipenem were read at 24 h to avoid false resistance. (cdc.gov)
  • Imipenem-susceptible isolates decreased from 94.1 percent of all tested isolates in 1999 to 72.4 in 2006. (rwjf.org)
  • Among the 25 RT017 isolates, 3 were imipenem-susceptible and from hospital B (MIC range 1.5-3 mg/L) ( Table 1 ). (cdc.gov)
  • Although the events observed (resistance rates) are susceptible to many influences the fact that they mirrored the consumption of imipenem as it rose and fell during the study period helps to provide evidence for causation. (neli.org.uk)
  • Imipenem has a broad spectrum of activity against aerobic and anaerobic, Gram-positive and Gram-negative bacteria. (wikipedia.org)
  • Imipenem acts as an antimicrobial through inhibiting cell wall synthesis of various Gram-positive and Gram-negative bacteria. (wikipedia.org)
  • It works by preventing bacteria from destroying imipenem. (medlineplus.gov)
  • Imipenem is a carbapenem antibacterial agent with a broad spectrum of activity against Gram-negative and Gram-positive bacteria. (clinicaltrials.gov)
  • Biological activities of biapenem, imipenem, and meropenem were compared with respect to permeability into Gram-negative bacteria, binding to penicillin-binding proteins (PBPs), and hydrolysis by beta-lactamases. (nih.gov)
  • Imipenem is considered to be generally a bactericidal agent, but may be static against some bacteria. (elephantcare.org)
  • (PDF) Ciprofloxacin interactions with imipenem and Review Article Comparative Study between Penicillin and Ampicillin S.K Sharma, Lalit Singh, Mechanism of Action (Penicillin and Ampicillin) Penicillin and other cell wall inhibitors are primarily specific against Gram -positive bacteria because of higher percentage of peptidoglycan in the cell walls of these organisms. (theluckettsfair.com)
  • The mode of action of imipenem allows for activity against Gram-positive and Gram-negative bacteria, cocci and bacilli, aerobes and anaerobes. (theluckettsfair.com)
  • Imipenem/cilastatin has the ability to kill a wide variety of bacteria. (bradtechguy.com)
  • Imipenem is active against most gram-positive, gram-negative, and anaerobic bacteria. (alpfmedical.info)
  • Clinical Infectious Diseases Advance Access published September 9, 2014 MAJOR ARTICLE Efficacy and Safety of Fosfomycin Plus Imipenem as Rescue Therapy for Complicated Bacteremia and Endocarditis Due to introduction to the internal family systems model pdf Antibacterial action: A bactericidal drug, imipenem inhibits bacterial cell wall synthesis. (theluckettsfair.com)
  • The antibacterial spectrum of imipenem is among the broadest of all of the p-lactam antibiotics. (alpfmedical.info)
  • Against non fermeters, meropenem was active on 84-94% of the strains, imipenem on 84-98% of the strains and piperacillin/tazobactam on 90-100% of the strains. (biomedcentral.com)
  • Bactericidal activity was achieved with all regimens except nafcillin monotherapy in test tubes but only with imipenem/vancomycin and nafcillin/vancomycin in fibrin clots infected with heterogeneous strains. (semanticscholar.org)
  • OXA-47 had a narrow spectrum of hydrolysis activity and did not hydrolyze ceftazidime or imipenem, as is found for the beta-lactamase (OXA-1) to which it is related. (nih.gov)
  • Monthly rates of resistance to imipenem, ceftazidime and piperacillin-tazobactam were significantly associated with imipenem prescription rates in the same and preceding month. (neli.org.uk)
  • The present study was undertaken to evaluate the screening tests like double disk synergy test (DDST) and disk potentiation test (DPT) using ceftazidime (CAZ) and imipenem (IPM) disks with chelating agents like EDTA and 2-MPA. (biomedcentral.com)
  • People who are allergic to penicillin and other β-lactam antibiotics should take caution if taking imipenem, as cross-reactivity rates are high. (wikipedia.org)
  • Imipenem is in a class of medications called carbapenem antibiotics. (medlineplus.gov)
  • Structurally, Imipenem is a beta-lactam antibiotics but differ from penicillins in having the thiazolidine sulfur atom replaced by carbon. (drugsdetails.com)
  • CNS adverse reactions, such as seizures, confusional states, and myoclonic activity, have been reported during treatment with imipenem/cilastatin, a component of RECARBRIO, especially when recommended dosages of imipenem were exceeded. (merckconnect.com)
  • The dosage form available for Dexamethasone/Imipenem/Cilastatin/Polymyxin B/Tobramycin is Otic Suspension. (wedgewoodpharmacy.com)
  • Dexamethasone/Imipenem/Cilastatin/Polymyxin B/Tobramycin is also available in this dosage form. (wedgewoodpharmacy.com)
  • Detailed information related to Imipenem-Cilastatin Injection's uses, composition, dosage, side effects and reviews is listed below. (salvavidaspharmaceutical.com)
  • [1] It is made from a combination of imipenem and cilastatin . (wikipedia.org)
  • The similar in vivo bactericidal effect was also observed in combination of imipenem and sulbactam. (clinicaltrials.gov)
  • Imipenem is rapidly degraded by the renal enzyme dehydropeptidase 1 when administered alone, and is almost always coadministered with cilastatin to prevent this inactivation. (wikipedia.org)
  • The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin. (dovepress.com)
  • To identify and review studies which have sought to define the pharmacokinetics of imipenem and cilastatin in patients receiving continuous renal replacement therapy (CRRT). (springer.com)
  • Total body clearance of imipenem during CRRT in patients suffering from acute renal failure was found to range between 89 and 149 ml/min. (springer.com)
  • Total body clearance of both imipenem and cilastatin was reduced in patients with chronic renal failure. (springer.com)
  • METHODS Patients with a clinical suspicion of pneumonia were randomised to receive either ciprofloxacin (800-1200 mg/day) or imipenem (2-4 g/day) in doses adjusted for renal function and specimens of the lower respiratory tract were taken. (bmj.com)
  • Cilastatin inhibits the metabolism of imipenem by DHP 1 on the brush borders of renal tubular cells. (elephantcare.org)
  • This serves two functions: it allows higher urine levels and may also protect against proximal renal tubular necrosis that can occur when imipenem is used alone. (elephantcare.org)
  • When given with cilastatin, imipenem is eliminated by both renal and non-renal mecha-nisms. (elephantcare.org)
  • Because imipenem is rapidly inactivated by renal dehydropeptidase I, it is given in combination with cilastatin, a DHP-I inhibitor which increases half-life and tissue penetration of imipenem. (bradtechguy.com)
  • The enzyme, dehydropeptidase I, present in renal tubules, converts imipenem to an inactive metabolite. (alpfmedical.info)
  • It is a broad-spectrum beta-lactam containing equal quantities of imipenem and cilastatin . (wikipedia.org)
  • OTHER NAME(S): Imipenem-Cilastatin Suspension For Reconstitution Imipenem is a broad-spectrum, semi-synthetic beta-lactam carbapenem derived from thienamycin, produced by Streptomyces cattleya. (bradtechguy.com)
  • Cilastatin helps Imipenem work more effectively. (medindia.net)
  • 500mg imipenem, 500mg cilastatin, and 20mg sodium bicarbonate power mixture for … Search results for Imipenem at Sigma-Aldrich. (bradtechguy.com)
  • The objective of the present proposal is to evaluate the effectiveness of combination therapy of imipenem and sulbactam in patients contracted with A. baumannii, and to correlate the clinical effect with the in vitro synergistic results. (clinicaltrials.gov)
  • Therefore, the in vitro activities of penicillin, ampicillin, imipenem, and vancomycin against 201 blood isolates of E. faecalis and 24 blood isolates of Enterococcus faecium were compared. (eurekamag.com)
  • Imipenem and cilastatin may also be used for purposes not listed in this medication guide. (wellspan.org)
  • Call your doctor for instructions if you miss a dose of imipenem and cilastatin. (wellspan.org)
  • Analysis of the appropriateness of imipenem/cilastatin indication, dose, and monitoring of seizure frequency was based on the package insert, updated published guidelines, and clinical judgment. (dovepress.com)
  • Uncomplicated gonorrhoea- As imipenem: 500 mg as single dose. (medindia.net)
  • Base dose on imipenem component. (oncologynurseadvisor.com)
  • If you miss a dose of Imipenem/Cilastatin , use it as soon as possible. (drugster.info)
  • Developmental toxicity studies with imipenem and cilastatin sodium (alone or in combination) administered to mice, rats, rabbits, and monkeys at doses 0.4 to 2.9 times the recommended human dose (RHD), (based on body surface area), showed no drug-induced fetal malformations [1] Cilastatin blocks the activity of dehydropeptidase I which prevents the breakdown of imipenem. (bradtechguy.com)
  • Dose is based on the imipenem component). (tbdrugmonographs.co.uk)
  • The dose that contains the instruction for the use of the substance in question for the medicinal product "Imipenem + Cilastatin" is intended for those patients whose body weight exceeds seventy kilograms. (behealthiers.com)
  • For an adult patient, the average daily dose of the drug "Imipenem and Cilastatin Jodas" is one to two grams, provided it is divided into three to four injections. (behealthiers.com)
  • Seven papers were identified which described the pharmacokinetics of imipenem in patients receiving CRRT. (springer.com)
  • Literature was primarily identified using Pharmline, Embase and Medline databases using the search terms 'imipenem,' 'haemofiltration,' 'haemodialysis' and 'pharmacokinetics. (springer.com)
  • Hashimoto S, Honda M, Yamaguchi M, Sekimoto M, Tanaka Y. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically iII. (springer.com)
  • Hypovolaemia and endotoxaemia only had an effect on imipenem pharmacokinetics. (ovid.com)
  • This is the original paper concerning the pharmacokinetics of imipenem. (blogspot.com)
  • Exposure of A. baumannii SMAL to subinhibitory concentrations of imipenem resulted in biofilm stimulation and increased production of iron uptake proteins. (biomedcentral.com)
  • Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. (nih.gov)
  • [1] Cilastatin blocks the activity of dehydropeptidase I which prevents the breakdown of imipenem. (wikipedia.org)
  • When given alone, imipenem is filtered in the glomerulus and when it reaches the proximal tubule, it is metabolized by a brush-border enzyme called dehydropeptidase I. As a result, under normal circumstances, only 5-20% of it is excreted unchanged in the urine. (blogspot.com)
  • To decrease metabolic clearance, imipenem is combined with cilastatin, an inhibitor of dehydropeptidase I. Additional pharmacokinetic information appears in Table 45.2. (alpfmedical.info)
  • 2020. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540281/0/Imipenem_Cilastatin. (unboundmedicine.com)
  • 2020. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/51400/all/imipenem_cilastatin. (unboundmedicine.com)
  • 2020. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51400/11.0/imipenem_cilastatin. (drugguide.com)
  • The cause of the mild, transient serum enzyme elevations during imipenem-cilastatin therapy is not known. (wikipedia.org)
  • The ARI 1 beta-lactamase hydrolysed penicillin, ampicillin and cephaloridine slowly during enzyme assay but inactivation of imipenem could only be demonstrated by microbiological means. (nih.gov)
  • This conformation resembles that of imipenem bound to the class A enzyme TEM-1 but is different from that of moxalactam bound to AmpC. (rcsb.org)
  • Patients who are allergic to penicillin, cephalosporins, and related drugs may react to imipenem. (wikipedia.org)
  • It hydrolyzed penicillins and imipenem but not expanded-spectrum cephalosporins. (nih.gov)
  • This study tried to investigate the efficacy of imipenem against VAP when it was infused within 180 min versus the efficacy when it was infused within 30-60 min. (pubmedcentralcanada.ca)
  • The efficacy of imipenem which was administered by intermittent infusion (30-60 min) within first year was compared with the efficacy of imipenem which was administered by extended infusion (180 min) within second year in the field of VAP curing and cost reduction. (pubmedcentralcanada.ca)
  • 1 Antimicrobial resistance surveillance serves as a fundamental basis for appreciating trends in resistance, developing accurate treatment guidelines, and evaluating the efficacy of interventions ( www.who.int/drugresistance/en/ ). (pubmedcentralcanada.ca)
  • These results suggest that clinafloxacin and imipenem have similar efficacy as empirical monotherapy in febrile granulocytopenic patients. (oup.com)
  • However, studies have shown false resistance to imipenem in commercially prepared test panels due to degradation of the drug or to a manufacturing problem where concentrations of imipenem were too low (1,2,4,5). (cdc.gov)
  • Imipenem concentrations were determined by high-performance liquid chromatography by using 11 different lots of MIC and breakpoint panels (139 to 893 days of age). (asm.org)
  • Despite the fact that original clinical isolate could be 'cured' of its resistance to imipenem and penicillins by growing in the presence of ethidium bromide with the concurrent loss of the ARI 1 enzymes, no resistance plasmid was visualised or transferred. (nih.gov)
  • At high doses, imipenem is seizurogenic. (wikipedia.org)
  • GIII: n=60 treated with 30mg/kg body weight Imipenem IM for four days, and GIV n=60 treated with diclofenac sodium plus Imipenem at the above doses IM for 4 days. (isaude.net)
  • Meropenem is slightly more active than imipenem against Gram-negative organisms. (cdc.gov)
  • Killing of immobilized organisms by imipenem and tobramycin were compared with free-cell experiments (inoculum c. 10(9) cells/mL). (biomedsearch.com)
  • Has slightly increased activity against gram-negative organisms and slightly decreased activity against staphylococci and streptococci compared to imipenem. (medscape.com)
  • The results indicated that there is a significant decrease in mortality, number of recurrent infection, and ICU stay length, and the number of mechanical ventilator days was associated with extended imipenem infusion during the second year of the study. (pubmedcentralcanada.ca)
  • The use of imipenem with extended infusion over 3 hours enhances its clinical outcomes in the treatment of VAP. (pubmedcentralcanada.ca)
  • imipenem/cilastatin is a topic covered in the Davis's Drug Guide . (unboundmedicine.com)
  • Davis's Drug Guide - OLD - USE 2.0 , www.drugguide.com/ddo/view/Davis-Drug-Guide/51400/11.0/imipenem_cilastatin. (drugguide.com)
  • Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by be. (nih.gov)
  • The consumption of imipenem was expressed in DDD/100 hospital days in the same periods. (srce.hr)
  • decreased significantly in the year 2000 (p=0.0052), especially in the first six months (p=0.021) when the lowest consumption of imipenem was recorded. (srce.hr)
  • The activity of piperacillin/tazobactam, ampicillin/sulbactam, imipenem and nafcillin alone and in combination with vancomycin was compared with vancomycin monotherapy against MRSA in test-tube time-kill studies and in infected fibrin clots. (semanticscholar.org)
  • The present study aimed to develop vancomycin and imipenem / cilastatin loaded core-shell nanofibers to facilitate the treatment of diabetic foot ulcers . (bvsalud.org)
  • Therefore, novel core-shell nanofibers composed of polyethylene oxide , chitosan , and vancomycin in shell and polyvinylpyrrolidone , gelatin , and imipenem / cilastatin in core compartments were prepared using the electrospinning technique . (bvsalud.org)